WO2021174048A1 - Gpr40 agonists - Google Patents

Gpr40 agonists Download PDF

Info

Publication number
WO2021174048A1
WO2021174048A1 PCT/US2021/019975 US2021019975W WO2021174048A1 WO 2021174048 A1 WO2021174048 A1 WO 2021174048A1 US 2021019975 W US2021019975 W US 2021019975W WO 2021174048 A1 WO2021174048 A1 WO 2021174048A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
formula
prodrug
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/019975
Other languages
English (en)
French (fr)
Inventor
Iyassu Sebhat
Shuwen He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kallyope Inc
Original Assignee
Kallyope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3173731A priority Critical patent/CA3173731A1/en
Priority to IL295825A priority patent/IL295825A/en
Priority to CN202180031976.3A priority patent/CN115667277A/zh
Priority to EP21759945.5A priority patent/EP4110788A4/en
Priority to PH1/2022/552277A priority patent/PH12022552277A1/en
Priority to KR1020227033245A priority patent/KR20220149558A/ko
Priority to MX2022010548A priority patent/MX2022010548A/es
Priority to JP2022551554A priority patent/JP7745559B2/ja
Application filed by Kallyope Inc filed Critical Kallyope Inc
Priority to BR112022017039A priority patent/BR112022017039A2/pt
Priority to AU2021228729A priority patent/AU2021228729A1/en
Publication of WO2021174048A1 publication Critical patent/WO2021174048A1/en
Priority to US17/745,126 priority patent/US12264171B2/en
Anticipated expiration legal-status Critical
Priority to US19/042,316 priority patent/US20250276989A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
    • C07C309/09—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing etherified hydroxy groups bound to the carbon skeleton
    • C07C309/10—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing etherified hydroxy groups bound to the carbon skeleton with the oxygen atom of at least one of the etherified hydroxy groups further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/04—Sulfinic acids; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/383—Cycloaliphatic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/568—Four-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • GPR40 AGONISTS CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of US Provisional Application No.62/983,438 filed on February 28, 2020, US Provisional Application No.63/076,113 filed on September 9, 2020, US Provisional Application No.63/117,074 filed on November 23, 2020, and US Provisional Application No.63/147,980 filed on February 10, 2021, each of which is incorporated herein by reference in its entirety.
  • BRIEF SUMMARY OF THE INVENTION Disclosed herein, in certain embodiments, are free fatty acid receptor 1 (GPR40) agonists useful for the treatment of conditions or disorders involving the gut-brain axis.
  • the GPR40 agonists are gut-restricted or selectively modulate GPR40 located in the gut.
  • the condition is selected from the group consisting of: central nervous system (CNS) disorders including mood disorders, anxiety, depression, affective disorders, schizophrenia, malaise, cognition disorders, addiction, autism, epilepsy, neurodegenerative disorders, Alzheimer’s disease, and Parkinson’s disease, Lewy Body dementia, episodic cluster headache, migraine, pain; metabolic conditions including diabetes and its complications such as chronic kidney disease/diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and cardiovascular disease, metabolic syndrome, obesity, dyslipidemia, and nonalcoholic steatohepatitis (NASH); eating and nutritional disorders including hyperphagia, cachexia, anorexia nervosa, short bowel syndrome, intestinal failure, intestinal insufficiency and other eating disorders; inflammatory disorders and autoimmune diseases such as inflammatory bowel disease, ulcerative colitis, Crohn’s disease, psoriasis
  • CNS central nervous system
  • Ring B is cycloalkylene or heterocycloalkylene; wherein the cycloalkylene or heterocycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents;
  • Ring A is carbocycle or heterocycle; wherein the carbocycle or heterocycle is unsubstituted or substituted with 1, 2, 3, 4, or 5 R A substituents;
  • each L A and L B is independently a bond or C 1- C 6 alkylene; wherein the alkylene is unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, -CN, -OH, -O-(C 1- C 6 alkyl), and C 1- C 6 alkyl; each R 10 is independently C 1- C 10 alkyl, C 2- C 10 alkenyl, C 2- C 10 alkynyl, C 3- C 10 cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl, or monocyclic heteroaryl; wherein each alkyl, alkenyl, alkyny
  • the compound is a compound of Formula (II):
  • the compound is a compound of Formula (III):
  • the compound is a compound of Formula (IV):
  • the compound is a compound of Formula (IVa) or Formula (IVb):
  • Formula (IVa) Formula (IVb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (V):
  • the compound is a compound of Formula (Va) or Formula (Vb):
  • Formula (Va) Formula (Vb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (VI):
  • the compound is a compound of Formula (Via) or Formula (VIb):
  • Formula (Via) Formula (VIb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (Vla-i) or Formula (VIb-i):
  • Formula (Vla-i) Formula (VIb-i) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (XV):
  • the compound is a compound of Formula (XVa-i):
  • the compound is a compound of Formula (VII):
  • the compound is a compound of Formula (Vila) or Formula (Vllb):
  • Formula (Vila) Formula (Vllb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (VIII):
  • the compound is a compound of Formula (Villa) or Formula (Vlllb):
  • Formula (Villa) Formula (Vlllb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (XIV):
  • the compound is a compound of Formula (XIVa-i):
  • compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, and at least one pharmaceutically acceptable excipient.
  • the condition or disorder is associated with GPR40 activity.
  • the condition or disorder is a metabolic disorder.
  • the condition or disorder is type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, nonalcoholic steatohepatitis, or hypertension.
  • the condition or disorder is a nutritional disorder.
  • the condition or disorder is short bowel syndrome, intestinal failure, or intestinal insufficiency.
  • the compound disclosed herein is gut-restricted. In some embodiments, the compound disclosed herein has low systemic exposure.
  • the methods disclosed herein further comprise administering one or more additional therapeutic agents to the subject.
  • the one or more additional therapeutic agents are selected from a TGR5 agonist, a GPR119 agonist, an SSTR5 antagonist, an SSTR5 inverse agonist, a CCK1 agonist, a PDE4 inhibitor, a DPP -4 inhibitor, a GLP-1 receptor agonist, a GOAT inhibitor, metformin, or combinations thereof.
  • the TGR5 agonist, GPR119 agonist, SSTR5 antagonist, SSTR5 inverse agonist or CCK1 agonist is gut-restricted.
  • GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis.
  • the GPR40 agonists are gut-restricted compounds.
  • the GPR40 agonists are full agonists or partial agonists.
  • C 1- C x includes C 1- C 2 , C 1- C 3 . . . C 1- C x.
  • a group designated as “C 1- C 4 ” indicates that there are one to four carbon atoms in the moiety, i.e., groups containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms.
  • C 1- C 4 alkyl indicates that there are one to four carbon atoms in the alkyl group, i.e., the alkyl group is selected from among methyl, ethyl, propyl, iso-propyl, n-butyl, iso- butyl, sec-butyl, and t-butyl.
  • Alkyl refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, or more preferably, from one to six carbon atoms, wherein an sp 3 -hybridized carbon of the alkyl residue is attached to the rest of the molecule by a single bond.
  • Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methy1- 1 -propyl, 2-methy1-2-propyl, 2-methy1- 1 -butyl, 3 -methy1- 1 -butyl, 2-methy1-3 -butyl, 2,2-dimethy1- 1 -propyl, 2-methy1- 1 -pentyl, 3- m ethy1- 1 -pentyl, 4-methy1- 1 -pentyl, 2-methy1-2-pentyl, 3-methy1-2-pentyl, 4-methy1-2-pentyl, 2,2-dimethy1- 1 -butyl, 3,3-dimethy1-1-butyl, 2-ethy1- 1 -butyl, n-butyl, isobutyl, sec-butyl, t-butyl,
  • C 1- C 6 alkyl means that the alkyl group consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.
  • the alkyl is a C 1- C 10 alkyl, a C 1- C 9 alkyl, a C 1- C 8 alkyl, a C 1- C 7 alkyl, a C 1- C 6 alkyl, a C 1- C 5 alkyl, a C 1- C 4 alkyl, a C 1- C 3 alkyl, a C 1- C 2 alkyl, or a Ci alkyl.
  • an alkyl group is optionally substituted as described below by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , - SR a , -OC(O)R a , -OC(O)-OR f , -N(R a ) 2 , -N + (R a ) 3 , -C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , - N(R a )C(O)OR f , -OC(O)-N(R a ) 2 , -N(R a )C(O)R a , -N(R a )S(O) t R f (where t is 1 or 2), -S
  • Alkenyl refers to an optionally substituted straight-chain, or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms, wherein an sp 2 -hybridized carbon or an sp 3 -hybridized carbon of the alkenyl residue is attached to the rest of the molecule by a single bond.
  • the group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers.
  • a numerical range such as “C 2 -C 6 alkenyl” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated.
  • the alkenyl is a C 2- C 10 alkenyl, a C 2 -C 9 alkenyl, a C 2- C 8 alkenyl, a C 2 -C 7 alkenyl, a C 2 -C 6 alkenyl, a C 2- C 5 alkenyl, a C 2 -C4 alkenyl, a C 2 -C 3 alkenyl, or a C 2 alkenyl.
  • an alkenyl group is optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
  • an alkenyl group is optionally substituted as described below by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R f , -OC(O)-OR f , -N(R a )2, -N + (R a ) 3 , - C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , -N(R a )C(O)OR f , -OC(O)-N(R a ) 2 , -N(R a )C(O)R f , - N(R a )S(O) t R f (where t is 1 or 2), -S(
  • Alkynyl refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms, wherein an sp-hybridized carbon or an sp 3 -hybridized carbon of the alkynyl residue is attached to the rest of the molecule by a single bond. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl and the like.
  • C 2 -C 6 alkynyl means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated.
  • the alkynyl is a C 2- C 10 alkynyl, a C 2 -C 9 alkynyl, a C 2- C 8 alkynyl, a C 2 -C 7 alkynyl, a C 2 -C 6 alkynyl, a C 2- C 8 alkynyl, a C 2 -C 4 alkynyl, a C 2 -C 3 alkynyl, or a C 2 alkynyl.
  • an alkynyl group is optionally substituted as described below by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)R a , -OC(O)-OR f , - N(R a ) 2 , -N + (R a ) 3 , -C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , -N(R a )C(O)OR f , -OC(O)-N(R a ) 2 , - N(R a )C(O)R f , -N(R a )S(O) t R f (where t is 1 or 2), -
  • Alkylene or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, «-butylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group are through one carbon in the alkylene chain or through any two carbons within the chain.
  • an alkylene group is optionally substituted as described below by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)R a , -OC(O)-OR f , -N(R a ) 2 , -N + (R a ) 3 , -C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , -N(R a )C(O)OR f , -OC(O)-N(R a ) 2 , -N(R a )C(O)R f , -N(R a )S(O) t R f (where t is 1 or 2), -S(
  • alkenylene or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms.
  • the alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • an alkenylene group is optionally substituted as described below by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R f , -OC(O)-OR f , -N(R a ) 2 , -N + (R a ) 3 , -C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , - N(R a )C(O)OR f , -OC(O)-N(R a ) 2 , -N(R a )C(O)R f , -N(R a )S(O) t R f (where t is 1 or 2), -
  • Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond, and having from two to twelve carbon atoms.
  • the alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • an alkynylene group is optionally substituted as described below by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, - OR a , -SR a , -OC(O)R a , -OC(O)-OR f , -N(R a ) 2 , -N + (R a ) 3 , -C(O)R a , -C(O)OR a , -C(O)N(R a ) 2 , - N(R a )C(O)OR f , -OC(O)-N(R a ) 2 , -N(R a )C(O)R f , -N(R a )S(O) t R f (where t is 1 or 2), -
  • Alkoxy or “alkoxyl” refers to a radical bonded through an oxygen atom of the formula -O-alkyl, where alkyl is an alkyl chain as defined above.
  • Aryl refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
  • the aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon atoms unless otherwise specified ⁇ i.e., from 6 to 18 carbon atoms), where at least one of the rings in the ring system is fully unsaturated, (i.e., it contains a cyclic, delocalized (4n+2) p-electron system in accordance with the Hiickel theory).
  • the ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene.
  • the aryl is a C 6- C 10 aryl.
  • the aryl is a phenyl.
  • aryl or the prefix “ar-“ (such as in “aralkyl”) is meant to include aryl radicals optionally substituted as described below by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -SR a , -R b -OC(O)-R a , -R b -OC(O)-OR f , -R b -OC(O)- N(R a ) 2 , -R b -N(R a ) 2 , -R b -N + (R a ) 3
  • arylene refers to a divalent radical derived from an “aryl” group as described above linking the rest of the molecule to a radical group.
  • the arylene is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • the arylene is a phenylene.
  • an arylene group is optionally substituted as described above for an aryl group.
  • Cycloalkyl refers to a stable, partially or fully saturated, monocyclic or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems.
  • Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms ( C 3- C 15 cycloalkyl), from three to ten carbon atoms (C 3- C 10 cycloalkyl), from three to eight carbon atoms ( C 3- C 8 cycloalkyl), from three to six carbon atoms ( C 3- C 6 cycloalkyl), from three to five carbon atoms ( C 3- C 8 cycloalkyl), or three to four carbon atoms ( C 3- C 4 cycloalkyl).
  • the cycloalkyl is a 3- to 6-membered cycloalkyl.
  • the cycloalkyl is a 5- to 6-membered cycloalkyl.
  • Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic cycloalkyls or carbocycles include, for example, adamantyl, norbornyl, decalinyl, bicyclo[l.l.l]pentyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, 7,7-dimethy1-bicyclo[2.2.1]heptanyl, and the like.
  • cycloalkyl is meant to include cycloalkyl radicals optionally substituted as described below by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -SR a , -R b -OC(O)-R a , -R b - 0C(O)-OR f , -R b -OC(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -N + (R a ) 3 , -R b -C
  • a “cycloalkylene” refers to a divalent radical derived from a “cycloalkyl” group as described above linking the rest of the molecule to a radical group.
  • the cycloalkylene is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • a cycloalkylene group is optionally substituted as described above for a cycloalkyl group.
  • Halo or “halogen” refers to bromo, chloro, fluoro or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.
  • Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more hydroxy radicals, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
  • Fluoroalkyl refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluorom ethyl, 2,2,2-trifluoroethyl, 1-fluoromethy1-2-fluoroethyl, and the like.
  • Haloalkoxy or “haloalkoxyl” refers to an alkoxyl radical, as defined above, that is substituted by one or more halo radicals, as defined above.
  • Fluoroalkoxy or “fluoroalkoxyl” refers to an alkoxy radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethoxy, difluoromethoxy, fluoromethoxy, and the like.
  • Haldroxyalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., hydroxymethyl, 1 -hydroxy ethyl, 2-hydroxy ethyl, 2- hydroxypropyl, 3-hydroxypropyl, 1,2-dihydroxy ethyl, 2,3-dihydroxypropyl, 2, 3, 4,5,6- pentahydroxyhexyl, and the like.
  • Heterocycloalkyl refers to a stable 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
  • the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized.
  • the heterocycloalkyl is a 3- to 8-membered heterocycloalkyl.
  • the heterocycloalkyl is a 3- to 6- membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl.
  • heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidin
  • heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. More preferably, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e., skeletal atoms of the heterocycloalkyl ring).
  • heterocycloalkyl is meant to include heterocycloalkyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b - OR a , -R b -SR a , -R b -OC(O)-R a , -R b -OC(O)-OR f , -R b -OC(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -N + (R a
  • N-heterocycloalkyl refers to a heterocycloalkyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocycloalkyl radical to the rest of the molecule is through a nitrogen atom in the heterocycloalkyl radical.
  • An N-heterocycloalkyl radical is optionally substituted as described above for heterocycloalkyl radicals.
  • C-heterocycloalkyl refers to a heterocycloalkyl radical as defined above and where the point of attachment of the heterocycloalkyl radical to the rest of the molecule is through a carbon atom in the heterocycloalkyl radical.
  • a C-heterocycloalkyl radical is optionally substituted as described above for heterocycloalkyl radicals.
  • a “heterocycloalkylene” refers to a divalent radical derived from a “heterocycloalkyl” group as described above linking the rest of the molecule to a radical group.
  • the heterocycloalkylene is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • a heterocycloalkylene group is optionally substituted as described above for a heterocycloalkyl group.
  • Heteroaryl refers to a radical derived from a 5- to 18-membered aromatic ring radical that comprises one to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur.
  • the heteroaryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) p-electron system in accordance with the Hiickel theory.
  • the heteroaryl is a 5- to 10-membered heteroaryl.
  • the heteroaryl is a monocyclic heteroaryl, or a monocyclic 5- or 6- membered heteroaryl. In some embodiments, the heteroaryl is a 6,5-fused bicyclic heteroaryl.
  • the heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quatemized.
  • the heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
  • heteroaryl is meant to include heteroaryl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -SR a , -R b -OC(O)-R a , -R b -OC(O)-OR f , -R b -OC(O)- N(R a ) 2 , -R b -N(R a ) 2 , -R b -N + (R a ) 3 ,
  • a “heteroarylene” refers to a divalent radical derived from a “heteroaryl” group as described above linking the rest of the molecule to a radical group.
  • the heteroarylene is attached to the rest of the molecule through a single bond and to the radical group through a single bond. Unless stated otherwise specifically in the specification, a heteroarylene group is optionally substituted as described above for a heteroaryl group.
  • an optionally substituted group may be unsubstituted (e.g., -CH 2 CH 3 ), fully substituted (e.g., -CF 2 CF 3 ), mono- substituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH 2 CHF 2 , -CH 2 CF 3 , -CF 2 CH 3 , -CFHCHF 2 , etc.).
  • substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups, potentially ad infinitum
  • modulate refers to an increase or decrease in the amount, quality, or effect of a particular activity, function or molecule.
  • agonists, partial agonists, inverse agonists, antagonists, and allosteric modulators of a G protein-coupled receptor are modulators of the receptor.
  • agonism refers to the activation of a receptor or enzyme by a modulator, or agonist, to produce a biological response.
  • agonist refers to a modulator that binds to a receptor or target enzyme and activates the receptor or enzyme to produce a biological response.
  • GPR40 agonist can be used to refer to a compound that exhibits an EC 50 with respect to GPR40 activity of no more than about 100 ⁇ M, as measured in the as measured in the inositol phosphate accumulation assay.
  • agonist includes full agonists or partial agonists.
  • full agonist refers to a modulator that binds to and activates a receptor or target enzyme with the maximum response that an agonist can elicit at the receptor or enzyme.
  • partial agonist refers to a modulator that binds to and activates a receptor or target enzyme, but has partial efficacy, that is, less than the maximal response, at the receptor or enzyme relative to a full agonist.
  • positive allosteric modulator refers to a modulator that binds to a site distinct from the orthosteric binding site and enhances or amplifies the effect of an agonist.
  • antagonism refers to the inactivation of a receptor or target enzyme by a modulator, or antagonist.
  • Antagonism of a receptor for example, is when a molecule binds to the receptor or target enzyme and does not allow activity to occur.
  • the term “antagonist” or “neutral antagonist” as used herein refers to a modulator that binds to a receptor or target enzyme and blocks a biological response.
  • SSTR5 antagonist can be used to refer to a compound that exhibits an IC 50 with respect to SSTR5 activity of no more than about 100 ⁇ M, as measured in the as measured in the inositol phosphate accumulation assay.
  • An antagonist has no activity in the absence of an agonist or inverse agonist but can block the activity of either, causing no change in the biological response.
  • the term “inverse agonist” refers to a modulator that binds to the same receptor or target enzyme as an agonist but induces a pharmacological response opposite to that agonist, i.e., a decrease in biological response.
  • negative allosteric modulator refers to a modulator that binds to a site distinct from the orthosteric binding site and reduces or dampens the effect of an agonist.
  • EC 50 is intended to refer to the concentration of a substance (e.g., a compound or a drug) that is required for 50% activation or enhancement of a biological process. In some instances, EC 50 refers to the concentration of agonist that provokes a response halfway between the baseline and maximum response in an in vitro assay. In some embodiments as used herein, EC 50 refers to the concentration of an agonist (e.g., a GPR40 agonist) that is required for 50% activation of a receptor or target enzyme (e.g., GPR40).
  • a substance e.g., a compound or a drug
  • IC 50 is intended to refer to the concentration of a substance (e.g., a compound or a drug) that is required for 50% inhibition of a biological process.
  • IC 50 refers to the half maximal (50%) inhibitory concentration (IC) of a substance as determined in a suitable assay.
  • an IC 50 is determined in an in vitro assay system.
  • IC 50 refers to the concentration of a modulator (e.g., an SSTR5 antagonist) that is required for 50% inhibition of a receptor or a target enzyme (e.g., SSTR5).
  • a modulator e.g., an SSTR5 antagonist
  • SSTR5 target enzyme
  • mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • gut-restricted refers to a compound, e.g., a GPR40 agonist, that is predominantly active in the gastrointestinal system.
  • the biological activity of the gut-restricted compound e.g., a gut-restricted GPR40 agonist, is restricted to the gastrointestinal system.
  • gastrointestinal concentration of a gut-restricted modulator is higher than the IC 50 value or the EC 50 value of the gut-restricted modulator against its receptor or target enzyme, e.g., GPR40, while the plasma levels of said gut-restricted modulator, e.g., gut-restricted GPR40 agonist, are lower than the IC 50 value or the EC 50 value of the gut-restricted modulator against its receptor or target enzyme, e.g., GPR40.
  • the gut-restricted compound e.g., a gut-restricted GPR40 agonist
  • the gut-restricted compound is non-systemic.
  • the gut-restricted compound e.g., a gut- restricted GPR40 agonist
  • the gut-restricted compound e.g., a gut-restricted GPR40 agonist
  • the gut-restricted compound is absorbed, but is rapidly metabolized to metabolites that are significantly less active than the modulator itself toward the target receptor or enzyme, i.e., a “soft drug.”
  • the gut-restricted compound e.g., a gut- restricted GPR40 agonist
  • the gut-restricted modulator e.g., a gut-restricted GPR40 agonist
  • the modulator e.g., a gut-restricted GPR40 agonist
  • the systemic exposure of a gut-restricted modulator, e.g., a gut-restricted GPR40 agonist is, for example, less than 100, less than 50, less than 20, less than 10, or less than 5 nM, bound or unbound, in blood serum.
  • the intestinal exposure of a gut-restricted modulator is, for example, greater than 1000, 5000, 10000, 50000, 100000, or 500000 nM.
  • a modulator e.g., a GPR40 agonist
  • a modulator e.g., a GPR40 agonist
  • a kinetophore optionally through a linker, which changes the pharmacokinetic profile of the modulator.
  • the gut-restricted GPR40 agonist is a soft drug.
  • soft drug refers to a compound that is biologically active but is rapidly metabolized to metabolites that are significantly less active than the compound itself toward the target receptor.
  • the gut-restricted GPR40 agonist is a soft drug that is rapidly metabolized in the blood to significantly less active metabolites.
  • the gut-restricted GPR40 agonist is a soft drug that is rapidly metabolized in the liver to significantly less active metabolites.
  • the gut-restricted GPR40 agonist is a soft drug that is rapidly metabolized in the blood and the liver to significantly less active metabolites.
  • the gut-restricted GPR40 agonist is a soft drug that has low systemic exposure.
  • the biological activity of the metabolite(s) is/are 10- fold, 20-fold, 50-fold, 100-fold, 500-fold, or 1000-fold lower than the biological activity of the soft drug gut-restricted GPR40 agonist.
  • kinetophore refers to a structural unit tethered to a small molecule modulator, e.g., a GPR40 agonist, optionally through a linker, which makes the whole molecule larger and increases the polar surface area while maintaining biological activity of the small molecule modulator.
  • the kinetophore influences the pharmacokinetic properties, for example solubility, absorption, distribution, rate of elimination, and the like, of the small molecule modulator, e.g., a GPR40 agonist, and has minimal changes to the binding to or association with a receptor or target enzyme.
  • a kinetophore is not its interaction with the target, for example a receptor, but rather its effect on specific physiochemical characteristics of the modulator to which it is attached, e.g., a GPR40 agonist.
  • kinetophores are used to restrict a modulator, e.g., a GPR40 agonist, to the gut.
  • the term “linked” as used herein refers to a covalent linkage between a modulator, e.g., a GPR40 agonist, and a kinetophore.
  • linkage can be through a covalent bond, or through a “linker.”
  • linker refers to one or more bifunctional molecules which can be used to covalently bond to the modulator, e.g., a GPR40 agonist, and kinetophore.
  • the linker is attached to any part of the modulator, e.g., a GPR40 agonist, so long as the point of attachment does not interfere with the binding of the modulator to its receptor or target enzyme.
  • the linker is non-cleavable.
  • the linker is cleavable.
  • the linker is cleavable in the gut.
  • cleaving the linker releases the biologically active modulator, e.g., a GPR40 agonist, in the gut.
  • GI system gastrointestinal system
  • GI tract gastrointestinal tract
  • the gastrointestinal tract includes the esophagus, stomach, small intestine, which includes the duodenum, jejunum, and ileum, and large intestine, which includes the cecum, colon, and rectum.
  • the GI system refers to the “gut,” meaning the stomach, small intestines, and large intestines or to the small and large intestines, including, for example, the duodenum, jejunum, and/or colon.
  • the gut-brain axis refers to the bidirectional biochemical signaling that connects the gastrointestinal tract (GI tract) with the central nervous system (CNS) through the peripheral nervous system (PNS) and endocrine, immune, and metabolic pathways.
  • the gut-brain axis comprises the GI tract; the PNS including the dorsal root ganglia (DRG) and the sympathetic and parasympathetic arms of the autonomic nervous system including the enteric nervous system and the vagus nerve; the CNS; and the neuroendocrine and neuroimmune systems including the hypothalamic-pituitary-adrenal axis (HPA axis).
  • the gut-brain axis is important for maintaining homeostasis of the body and is regulated and modulates physiology through the central and peripheral nervous systems and endocrine, immune, and metabolic pathways.
  • the gut-brain axis modulates several important aspects of physiology and behavior. Modulation by the gut-brain axis occurs via hormonal and neural circuits. Key components of these hormonal and neural circuits of the gut-brain axis include highly specialized, secretory intestinal cells that release hormones (enteroendocrine cells or EECs), the autonomic nervous system (including the vagus nerve and enteric nervous system), and the central nervous system. These systems work together in a highly coordinated fashion to modulate physiology and behavior.
  • CNS central nervous system
  • Diseases and conditions affected by the gut-brain axis include central nervous system (CNS) ⁇ isorders including mood disorders, anxiety, depression, affective disorders, schizophrenia, malaise, cognition disorders, addiction, autism, epilepsy, neurodegenerative disorders, Alzheimer's disease, and Parkinson's disease, Lewy Body dementia, episodic cluster headache, migraine, pain; metabolic conditions including diabetes and its complications such as chronic kidney disease/diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and cardiovascular disease, metabolic syndrome, obesity, dyslipidemia, and nonalcoholic steatohepatitis (NASH); eating and nutritional disorders including hyperphagia, cachexia, anorexia nervosa, short bowel syndrome, intestinal failure, intestinal insufficiency and other eating disorders; inflammatory disorders and autoimmune diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, p
  • Free fatty acid receptor 1 (FFA1, FFAR1), also known as GPR40, is a class A G-protein coupled receptor. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.
  • GPR40 is expressed in enteroendocrine cells and pancreatic islet b cells. In some instances, GPR40 is expressed in enteroendocrine cells.
  • GPR40 agonists or partial agonists may be useful in the treatment of metabolic diseases such as obesity, diabetes, and NASH, and other diseases involving the gut-brain axis.
  • modulators of GPR40 induce insulin secretion.
  • modulators of GPR40 induce an increase in cytosolic Ca 2+ .
  • modulators of GPR40 induce higher levels of intracellular cAMP.
  • GPR40 modulation is in enteroendocrine cells.
  • modulators of GPR40 for example, GPR40 agonists or partial agonists, induce the secretion of GLP-1, GLP-2, GIP, PYY, CCK, or other hormones.
  • modulators of GPR40 induce the secretion of GLP-1, GIP, CCK or PYY. In some instances, modulators of GPR40, for example, GPR40 agonists, induce the secretion of GLP-1.
  • the GPR40 receptor modulator is a GPR40 agonist or partial agonist. In some embodiments, the GPR40 receptor modulator is a GPR40 agonist. In some embodiments, the GPR40 receptor modulator is a GPR40 partial agonist. In some embodiments, the GPR40 receptor modulator is a GPR40 positive allosteric modulator. In some embodiments, the GPR40 modulator is a gut-restricted GPR40 modulator. In some embodiments, the GPR40 modulator is a soft drug.
  • the condition or disorder involving the gut-brain axis is selected from the group consisting of: central nervous system (CNS) ⁇ isorders including mood disorders, anxiety, depression, affective disorders, schizophrenia, malaise, cognition disorders, addiction, autism, epilepsy, neurodegenerative disorders, Alzheimer's disease, and Parkinson's disease, Lewy Body dementia, episodic cluster headache, migraine, pain; metabolic conditions including diabetes and its complications such as chronic kidney disease/diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and cardiovascular disease, metabolic syndrome, obesity, dyslipidemia, and nonalcoholic steatohepatitis (NASH); eating and nutritional disorders including hyperphagia, cachexia, anorexia nervosa, short bowel syndrome, intestinal failure, intestinal insufficiency and other eating disorders; inflammatory disorders and autoimmune diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, celiac disease, and enteritis,
  • CNS central nervous system
  • the condition is a metabolic disorder.
  • the metabolic disorder is type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, nonalcoholic steatohepatitis, or hypertension.
  • the metabolic disorder is diabetes.
  • the metabolic disorder is obesity.
  • the metabolic disorder is nonalcoholic steatohepatitis.
  • the condition involving the gut-brain axis is a nutritional disorder.
  • the nutritional disorder is short bowel syndrome, intestinal failure, or intestinal insufficiency.
  • the nutritional disorder is short bowel syndrome.
  • the condition involving the gut-brain axis is enteritis.
  • the condition involving the gut-brain axis is chemotherapy-induced enteritis or radiation-induced enteritis. In some embodiments, the condition involving the gut-brain axis is weight loss or preventing weight gain or weight regain. In some embodiments, the condition involving the gut- brain axis is weight loss or preventing weight gain or weight regain post-bariatric surgery. In some embodiments, the condition involving the gut-brain axis is weight loss or preventing weight gain or weight regain, wherein the subject has had bariatric surgery.
  • activation of GPR40 by a GPR40 agonist recapitulates the lipotoxicity of free fatty acids on pancreatic beta-cells.
  • activation of GPR40 by a GPR40 agonist leads to beta-cell degeneration, islet insulin depletion, glucose intolerance and hyperglycemia.
  • the detrimental effects on beta-cells by a GPR40 agonist may be mediated through ER stress and NF-kB signaling pathways.
  • differentiation of deleterious systemic effects of a GPR40 agonist on beta-cell function and viability from beneficial, gut-driven effects would be critical for the development of a GPR40 agonist for the treatment of disease.
  • the GPR40 agonist is gut-restricted. In some embodiments, the GPR40 agonist is designed to be substantially non-permeable or substantially non-bioavailable in the blood stream. In some embodiments, the GPR40 agonist is designed to activate GPR40 activity in the gut and is substantially non-systemic. In some embodiments, the GPR40 agonist has low systemic exposure.
  • a gut-restricted GPR40 agonist has low oral bioavailability. In some embodiments, a gut-restricted GPR40 agonist has ⁇ 40 % oral bioavailability, ⁇ 30 % oral bioavailability, ⁇ 20% oral bioavailability, ⁇ 10% oral bioavailability, ⁇ 8% oral bioavailability, ⁇ 5% oral bioavailability, ⁇ 3% oral bioavailability, or ⁇ 2% oral bioavailability.
  • the unbound plasma levels of a gut-restricted GPR40 agonist are lower than the EC 50 value of the GPR40 agonist against GPR40. In some embodiments, the unbound plasma levels of a gut-restricted GPR40 agonist are significantly lower than the EC 50 value of the gut-restricted GPR40 agonist against GPR40. In some embodiments, the unbound plasma levels of the GPR40 agonist are 2-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, or 100-fold lower than the EC 50 value of the gut-restricted GPR40 agonist against GPR40.
  • the unbound plasma levels of the GPR40 agonist are greater than 2-fold, greater than 10-fold, greater than 20-fold, greater than 30-fold, greater than 40-fold, greater than 50- fold, or greater than 100-fold lower than the EC 50 value of the gut-restricted GPR40 agonist against GPR40.
  • a gut-restricted GPR40 agonist has low systemic exposure.
  • the systemic exposure of a gut-restricted GPR40 agonist is, for example, less than 500, less than 200, less than 100, less than 50, less than 20, less than 10, or less than 5 nM, bound or unbound, in blood serum.
  • the systemic exposure of a gut- restricted GPR40 agonist is, for example, less than 500, less than 200, less than 100, less than 50, less than 20, less than 10, or less than 5 ng/mL, bound or unbound, in blood serum.
  • a gut-restricted GPR40 agonist has low pancreatic exposure.
  • the pancreatic exposure of a gut-restricted GPR40 agonist is, for example, less than 500, less than 200, less than 100, less than 50, less than 20, less than 10, or less than 5 nM in the pancreas.
  • the pancreatic exposure of a gut-restricted GPR40 agonist is, for example, less than 500, less than 200, less than 100, less than 50, less than 20, less than 10, or less than 5 ng/mL in the pancreas.
  • a gut-restricted GPR40 agonist has low permeability. In some embodiments, a gut-restricted GPR40 agonist has low intestinal permeability. In some embodiments, the permeability of a gut-restricted GPR40 agonist is, for example, less than 5.0x10 -6 cm/s, less than 2.0> ⁇ 10 -6 cm/s, less than 1.5x10 -6 cm/s, less than 1.0x10 -6 cm/s, less than 0.75x10 -6 cm/s, less than 0.50x10 -6 cm/s, less than 0.25x10 -6 cm/s, less than 0.10x10 -6 cm/s, or less than 0.05x10 -6 cm/s.
  • a gut-restricted GPR40 agonist has low absorption. In some embodiments, the absorption of a gut-restricted GPR40 agonist is less than less than 40%, less than 30%, less than 20%, or less than 10%, less than 5%, or less than 1%.
  • a gut-restricted GPR40 agonist has high plasma clearance. In some embodiments, a gut-restricted GPR40 agonist is undetectable in plasma in less than 8 hours, less than 6 hours, less than 4 hours, less than 3 hours, less than 120 min, less than 90 min, less than 60 min, less than 45 min, less than 30 min, or less than 15 min.
  • a gut-restricted GPR40 agonist is rapidly metabolized upon administration.
  • the internal ester of the compounds described herein is rapidly cleaved upon administration.
  • a gut-restricted GPR40 agonist has a short half-1ife.
  • the half-1ife of a gut-restricted GPR40 agonist is less than less than 8 hours, less than 6 hours, less than 4 hours, less than 3 hours, less than 120 min, less than 90 min, less than 60 min, less than 45 min, less than 30 min, or less than 15 min.
  • the metabolites of a gut-restricted GPR40 agonist have rapid clearance.
  • the metabolites of a gut-restricted GPR40 agonist are undetectable in less than 8 hours, less than 6 hours, less than 4 hours, less than 3 hours, less than 120 min, less than 90 min, less than 60 min, less than 45 min, less than 30 min, or less than 15 min.
  • the metabolites of a gut-restricted GPR40 agonist have low bioactivity.
  • the EC 50 value of the metabolites of a gut-restricted GPR40 agonist is 10-fold, 20- fold, 30-fold, 40-fold, 50-fold, 100-fold, 500-fold, or 1000-fold higher than the EC 50 value of the gut-restricted GPR40 agonist against GPR40.
  • the metabolites of a gut- restricted GPR40 agonist have rapid clearance and low bioactivity.
  • the GPR40 modulator is gut- restricted. In some embodiments, the GPR40 modulator is a gut-restricted GPR40 agonist. In some embodiments, the GPR40 agonist is a gut-restricted GPR40 full agonist. In some embodiments, the GPR40 agonist is a gut-restricted GPR40 partial agonist. In some embodiments, the GPR40 agonist is covalently bonded to a kinetophore. In some embodiments, the GPR40 agonist is covalently bonded to a kinetophore through a linker.
  • R 5 is C 1 -C 6 alkyl, C 3- C 6 cycloalkyl, phenyl, or -(C 1 -C 6 alkyl)-phenyl; wherein each alkyl, cycloalkyl, and phenyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, -CN, -OH, -O-(Ci- C6 alkyl), C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 hydroxyalkyl, -O-(C 1- C 6 fluoroalkyl), C 3- C 6 cycloalkyl, and 3- to 6-membered heterocycloalkyl; each R 6 is independently hydrogen, C 1 -C 6 alkyl, C 3- C 6 cycloalkyl, phenyl, or-(C 1- C 6 alkyl)-phenyl; wherein each alkyl, cyclo
  • R 1 , R 2 , and R 3 are each independently hydrogen, halogen, -OH, -O-(C 1- C 6 alkyl), C 1- C 6 alkyl, C 3- C 6 cycloalkyl, or 3- to 6-membered heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, -CN, -OH, -O-(C 1- C 6 alkyl), and C 1- C 6 alkyl;
  • R 4 is C 1- C 6 alkyl, C 3- C 6 cycloalkyl, or 3- to 6-membered heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, -CN, -OH, -O-(Ci- C 6 alkyl), and C 1- C 6 alkyl;
  • Y 1 , Y 2 , Y 3 , and Y 4 are each independently N, CH, or C-R Y ; each R Y is independently halogen, -CN, -OH, -O-(C 1- C 6 alkyl), -NH2, -NH-(C I -C 6 alkyl), -N(C 1 -C 6 alkyl)2, C 1- C 6 alkyl, C 3- C 6 cycloalkyl, or 3- to 6-membered heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, -CN, -OH, -O-(C 1- C 6 alkyl), and C 1- C 6 alkyl;
  • L 1 is -O-, -NR 7 -, *-O-CH 2 -, *-CH 2 -O-, *-NR 7 -CH 2 -, *-CH 2 -NR 7 -, *-NR 7 -C(O)-, *-C(O)- NR 7 -, or *-C(O)-CH 2 -; wherein * represents the connection to Ring B;
  • R 7 is hydrogen, C 1- C 6 alkyl, or C 3- C 6 cycloalkyl
  • Ring B is cycloalkylene or heterocycloalkylene; wherein the cycloalkylene or heterocycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents;
  • Ring A is carbocycle or heterocycle; wherein the carbocycle or heterocycle is unsubstituted or substituted with 1, 2, 3, 4, or 5 R A substituents;
  • each R B is independently halogen, C 1- C 10 alkyl, C 2- C 10 alkenyl, C 2- C 10 alkynyl, C 1- C 10 heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, fluoroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently unsubstituted or substituted with 1, 2,
  • each L A and L B is independently a bond or C 1 -C 6 alkylene; wherein the alkylene is unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, -CN, -OH, -O-(C 1- C 6 alkyl), and C 1 -C 6 alkyl; each R 10 is independently C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, 3- to 10-membered heterocycloalkyl, phenyl, or monocyclic heteroaryl; wherein each al
  • Y 1 , Y 2 , Y 3 , and Y 4 are each independently N, CH, or C-R Y ; wherein one or two of Y 1 , Y 2 , Y 3 , and Y 4 is N. In some embodiments, one of Y 1 , Y 2 , Y 3 , and Y 4 is N. In some embodiments, Y 1 is N, and Y 2 , Y 3 , and Y 4 are each independently CH, or C-R Y .
  • Y 2 is N, and Y 1 , Y 3 , and Y 4 are each independently CH, or C- R Y .
  • Y 3 is N, and Y 1 , Y 2 , and Y 4 are each independently CH, or C-R Y .
  • Y 4 is N, and Y 1 , Y 2 , and Y 3 are each independently CH, or C-R Y .
  • Y 1 , Y 2 , Y 3 , and Y 4 are each independently CH, or C-R Y .
  • each R Y is independently F, Cl, Br, -CN, -OH, - O-(C 1- C 6 alkyl), C 1- C 6 alkyl.
  • each R Y is independently F, Cl, Br, -CN, - OH, -OCH 3 , -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )CH 2 CH 3 , or -O(CH 3 ) 3 .
  • each R Y is F.
  • Y 1 , Y 2 , Y 3 , and Y 4 are each independently N, CH, or C-R Y ; and each R Y is independently F, Cl, Br, -CN, -OH, -O-(C 1- C 6 alkyl), C 1- C 6 alkyl.
  • Y 1 , Y 2 , Y 3 , and Y 4 are each independently N or CH.
  • Y 1 , Y 2 , Y 3 , and Y 4 are each independently N, CH, or CF. In some embodiments, Y 1 , Y 2 , Y 3 , and Y 4 are each independently N or CH. In some embodiments, Y 1 is N, and Y 2 , Y 3 , and Y 4 are each independently CH. In some embodiments,
  • Y 2 is N, and Y 1 , Y 3 , and Y 4 are each independently CH. In some embodiments, Y 3 is N, and Y 1 , Y 2 , and Y 4 are each independently CH. In some embodiments, Y 1 , Y 2 , Y 3 , and Y 4 are each CH.
  • the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula 2: or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • Y 2 is CH or N. In some embodiments, Y 2 is N. In some embodiments, Y 2 is CH.
  • the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (II): or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • R 1 , R 2 , and R 3 are each independently hydrogen, halogen, or C 1 -C 6 alkyl.
  • R 1 , R 2 , and R 3 are each independently hydrogen, F, Cl, Br, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , - CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , or -C(CH 3 )3.
  • R 1 , R 2 , and R 3 are each independently hydrogen, -F, -Cl, or C 1 -C 4 alkyl. In some embodiments, R 1 , R 2 , and R 3 are each independently hydrogen, F, or-CH 3 .
  • R 4 is C 1- C 6 alkyl or C 3- C 6 cycloalkyl.
  • R 4 is -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , - CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , — C(CH 3 ) 3 , cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 4 is -CH 3 , -CH 2 CH 3 , cyclopropyl, or cyclobutyl. In some embodiments, R 4 is -CH 2 CH 3 . In some embodiments, R 4 is cyclopropyl.
  • R 1 , R 2 , and R 3 are each independently hydrogen, halogen, or C 1 -C 6 alkyl; and R 4 is C 1 -C 6 alkyl or C 3- C 6 cycloalkyl.
  • R 1 , R 2 , and R 3 are each independently hydrogen, halogen, or C 1 -C 4 alkyl; and R 4 is unsubstituted C 3- C 6 cycloalkyl.
  • the compound of Formula (I) or (2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (3):
  • Y 2 is N.
  • Y 2 is CH.
  • the compound of Formula (I) or (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (III):
  • R 1 , R 2 , and R 3 are each independently hydrogen, -F, or methyl.
  • R 3 is hydrogen; and R 1 and R 2 are each independently hydrogen, -F, or methyl.
  • the compound of Formula (I), (2), or (3), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (4):
  • the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (IV):
  • L 1 is *-O-CH 3 -, *- CH 2 -O-, *-NR 7 -CH 2 -, *-NR 7 -C(O)-, *-C(O)-NR 7 -, or *-C(O)-CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -C(O)- or *-C(O)-NR 7 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-C(O)-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 - or *-CH 3 -O-; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, R 7 is hydrogen or C 1- C 6 alkyl.
  • R 7 is hydrogen, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, - CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , or -C(CH 3 )3.
  • R 7 is hydrogen or methyl. In some embodiments, R 7 is hydrogen.
  • the compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (IVa) or Formula (IVb):
  • Formula (IVa) Formula (IVb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (IVa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (IVb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • Ring B is C 3- C 10 cycloalkylene or 3- to 10-membered heterocycloalkylene. In some embodiments, Ring B is C 3 - C 10 cycloalkylene or 3- to 10-membered heterocycloalkylene; wherein the cycloalkylene or heterocycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents.
  • Ring B is bicyclic carbocycle or bicyclic heterocycle.
  • Ring B is bicyclic carbocycle or bicyclic heterocycle; wherein the carbocycle or heterocycle is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents.
  • Ring B is bicyclic heterocycle; wherein the bicyclic heterocycle is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents.
  • Ring B is bicyclic carbocycle; wherein the bicyclic carbocycle is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents.
  • Ring A is aryl, heteroaryl, C 3- C 10 cycloalkyl, or 3- to 10-membered heterocycloalkyl.
  • Ring A is aryl, heteroaryl, C 3- C 10 cycloalkyl, or 3- to 10-membered heterocycloalkyl; wherein the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is unsubstituted or substituted with 1, 2, 3, 4, or 5 R A substituents.
  • Ring B is C 3- C 10 cycloalkylene, or 3- to 10-membered heterocycloalkylene; wherein the cycloalkylene or heterocycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents; and Ring A is aryl, heteroaryl, C 3- C 10 cycloalkyl, or 3- to 10-membered heterocycloalkyl; wherein the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is unsubstituted or substituted with 1, 2, 3, 4, or 5 R A substituents.
  • Ring B is 3- to 6-membered heterocycloalkylene; wherein the heterocycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents.
  • Ring B is 3- to 6-membered heterocycloalkylene; wherein the heterocycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents; each R B is independently halogen, C 1- C 6 alkyl, or C 1- C 6 fluoroalkyl.
  • Ring B is azetidinylene, pyrrolidinylene, or piperidinylene; wherein the heterocycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents; each R B is independently halogen, C 1- C 6 alkyl, or C 1- C 6 fluoroalkyl.
  • Ring B is unsubstituted 3- to 6-membered heterocycloalkylene.
  • Ring B is unsubstituted piperidinylene.
  • Ring B is unsubstituted pyrrolidinylene.
  • Ring B is unsubstituted azetidinylene.
  • Ring B is C 3- C 6 cycloalkylene; wherein the cycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents.
  • Ring B is C 3- C 6 cycloalkylene; wherein the cycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents; each R B is independently halogen, C 1- C 6 alkyl, or C 1- C 6 fluoroalkyl.
  • Ring B is unsubstituted C 3- C 6 cycloalkylene. In some embodiments, Ring B is cyclohexylene; wherein the cyclohexylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents; each R B is independently halogen, C 1- C 6 alkyl, or C 1- C 6 fluoroalkyl. In some embodiments, Ring B is unsubstituted cyclohexylene.
  • each R B is independently halogen, C 1- C 6 alkyl, or C 1- C 6 fluoroalkyl.
  • each R B is independently F, Cl, Br, -CF 3 , -CHF 2 , -CH 2 F, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , - CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )CH 2 CH 3 , or -C(CH 3 ) 3 .
  • Ring A is aryl or heteroaryl; wherein the aryl or heteroaryl is unsubstituted or substituted with 1, 2, or 3 R A substituents.
  • L 2 is a bond or C 1- C 6 alkylene.
  • L 2 is a bond or C 1- C 6 alkylene; wherein the alkylene is unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of- OH, C 1- C 6 alkyl, and -O-(C 1- C 6 alkyl).
  • Ring B is 3- to 6-membered heterocycloalkylene; wherein the heterocycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents; each R B is independently halogen, C 1- C 6 alkyl, or C 1- C 6 fluoroalkyl; L 2 is a bond or C 1- C 6 alkylene; wherein the alkylene is unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of -OH, C 1- C 6 alkyl, and -O-(C 1- C 6 alkyl); and Ring A is aryl or heteroaryl; wherein the aryl or heteroaryl is unsubstituted or substituted with 1, 2, or 3 R A substituents.
  • the compound of Formula (I), (2), (3), or (4), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (5):
  • Formula (5) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof wherein Y 2 is CH or N; and p and q are each independently 1 or 2. In some embodiments, Y 2 is N. In some embodiments, Y 2 is CH. In some embodiments, p is 1 and q is 1. In some embodiments, p is 1 and q is 2. In some embodiments, p is 2 and q is 2. [00124] In some embodiments, the compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, is a compound of Formula (V):
  • a compound of Formula (V) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, is a compound of Formula (V-i):
  • a compound of Formula (V) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, is a compound of Formula (V-ii):
  • L 1 is *-O-CH 2 -, *-CH 2 -O-, *-NR 7 -CH 2 -, *-NR 7 -C(O)-, *-C(O)-NR 7 -, or *-C(O)-CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -C(O)- or *-C(O)-NR 7 -; wherein * represents the connection to Ring B.
  • L 1 is *-C(O)-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 - or *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, R 7 is hydrogen or C 1- C 6 alkyl.
  • R 7 is hydrogen, -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , or -C(CH 3 )3.
  • R 7 is hydrogen or methyl. In some embodiments, R 7 is hydrogen.
  • the compound of Formula (I), (II), (III), (IV), or (V), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Va) or Formula (Vb):
  • Formula (Va) Formula (Vb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • p and q are each independently 1 or 2.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • the compound of Formula (I), (II), (III), (IV), or (V), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Va), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (Vb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • a compound of Formula (Va), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Va-i):
  • a compound of Formula (Vb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vb-i):
  • a compound of Formula (Va), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Va-ii):
  • a compound of Formula (Vb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vb-ii):
  • the compound of Formula (I), (2), (3), or (4), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (6):
  • Y 2 is N.
  • Y 2 is CH.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • the compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (VI):
  • a compound of Formula (VI), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (VI-i):
  • a compound of Formula (VI), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (V1-ii):
  • L 1 is *-O-CH 2 -, *-CH 2 -O-, *-NR 7 - CH 2 -, *-NR 7 -C(O)-, *-C(O)-NR 7 -, or *-C(O)-CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -C(O)- or *-C(O)-NR 7 -; wherein * represents the connection to Ring B.
  • L 1 is *-C(O)-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 - or *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, R 7 is hydrogen or C 1 -C 6 alkyl.
  • R 7 is hydrogen, -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , or — C(CH 3 )3.
  • R 7 is hydrogen or methyl. In some embodiments, R 7 is hydrogen.
  • a compound of Formula (I), (II), (III), (IV), or (VI), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Via) or Formula (VIb):
  • Formula (Via) Formula (VIb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • p and q are each independently 1 or 2.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • the compound of Formula (I), (II), (III), (IV), or (VI), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Via), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (VIb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • a compound of Formula (Via), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vla-i):
  • a compound of Formula (VIb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (VIb-i):
  • a compound of Formula (Via), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vla-ii):
  • a compound of Formula (VIb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (VIb-ii):
  • the compound of Formula (I), (2), (3), or (4), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (7):
  • Y 2 is N.
  • Y 2 is CH.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • the compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (VII):
  • a compound of Formula (VII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vl1-i):
  • a compound of Formula (VII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vl1-ii):
  • L 1 is *-C(O)-NR 7 -, or *-C(O)-CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-C(O)-NR 7 -; wherein * represents the connection to Ring B.
  • L 1 is *-C(O)-CH 2 -; wherein * represents the connection to Ring B.
  • R 7 is hydrogen or C 1- C 6 alkyl.
  • R 7 is hydrogen, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, - CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , or-C(CH 3 ) 3.
  • R 7 is hydrogen or methyl. In some embodiments, R 7 is hydrogen.
  • a compound of Formula (I), (II), (III), (IV), or (VII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vila) or Formula (Vllb):
  • Formula (Vila) Formula (Vllb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • p and q are each independently 1 or 2.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • the compound of Formula (I), (II), (III), (IV), or (VII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vila), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (Vllb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • a compound of Formula (Vila), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vlla-i):
  • a compound of Formula (Vllb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vllb-i):
  • a compound of Formula (Vila), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vlla-ii):
  • a compound of Formula (Vllb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vllb-ii):
  • Ring B is C 3- C 6 cycloalkylene; wherein the cycloalkylene is unsubstituted or substituted with 1, 2, 3, or 4 R B substituents; each R B is independently halogen, C 1- C 6 alkyl, or C 1- C 6 fluoroalkyl; L 2 is a bond or C 1- C 6 alkylene; wherein the alkylene is unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of -OH, C 1- C 6 alkyl, and -O-(C 1- C 6 alkyl); and Ring A is aryl or heteroaryl; wherein the aryl
  • the compound of Formula (I), (2), (3), or (4), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (8):
  • Y 2 is N.
  • Y 2 is CH.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • the compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (VIII):
  • a compound of Formula (VIII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vll1-i):
  • a compound of Formula (VIII) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, is a compound of Formula (VIII-ii):
  • a compound of Formula (VIII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (VllI- ii):
  • L 1 is *-O-CH 2 -, *-CH 2 -O-, *-NR 7 - CH 2 -, *-NR 7 -C(O)-, *-C(O)-NR 7 -, or *-C(O)-CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -C(O)- or *-C(O)-NR 7 -; wherein * represents the connection to Ring B.
  • L 1 is *-C(O)-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 - or *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, R 7 is hydrogen or C 1- C 6 alkyl.
  • R 7 is hydrogen, -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , or -C(CH 3 )3.
  • R 7 is hydrogen or methyl. In some embodiments, R 7 is hydrogen.
  • a compound of Formula (I), (II), (III), (IV), or (VIII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Villa) or Formula (Vlllb):
  • Formula (Villa) Formula (Vlllb) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • p and q are each independently 1 or 2.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • the compound of Formula (I), (II), (III), (IV), or (VIII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Villa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (Vlllb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • a compound of Formula (Villa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vllla-i):
  • a compound of Formula (Villa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vllla-ii):
  • Formula (Vllla-ii) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vllla-iii):
  • a compound of Formula (VllIb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vlllb-i):
  • a compound of Formula (VIIIb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (VIIIb-ii):
  • a compound of Formula (VllIb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (Vlllb-iii):
  • Formula (Vlllb-iii) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (14):
  • Y 2 is N.
  • Y 2 is CH.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • n is 1 or 2.
  • n is 1.
  • n is 2.
  • W is N.
  • W is CH.
  • W is CR A .
  • W is N; n is 1 or 2; p is 1 or 2; and q is 1 or 2. In some embodiments, W is N; n is 2; p is 2; and q is 2. . In some embodiments, W is CH; n is 1 or 2; p is 1 or 2; and q is 1 or 2. In some embodiments, W is CH; n is 2; p is 2; and q is 2. In some embodiments, W is CH and Y 2 is N. In some embodiments, W is N and Y 2 is N.
  • the compound of Formula (I), (II), (III), (IV), or (VIII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XIV):
  • W is N; n is 2; p is 2; and q is 2. .
  • W is CH; n is 1 or 2; p is 1 or 2; and q is 1 or 2.
  • W is CH; n is 2; p is 2; and q is 2.
  • a compound of Formula (XIV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XlV-i):
  • a compound of Formula (XIV) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, is a compound of Formula (XIV-ii):
  • a compound of Formula (XIV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XlV-iii):
  • L 1 is *-O-CH 2 -, *-CH 2 -O-, *-NR 7 - CH 2 -, *-NR 7 -C(O)-, *-C(O)-NR 7 -, or *-C(O)-CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -C(O)- or *-C(O)-NR 7 -; wherein * represents the connection to Ring B.
  • L 1 is *-C(O)-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 - or *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, R 7 is hydrogen or C 1- C 6 alkyl.
  • R 7 is hydrogen, -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , or -C(CH 3 )3.
  • R 7 is hydrogen or methyl. In some embodiments, R 7 is hydrogen.
  • a compound of Formula (I), (II), (III), (IV), (VIII), or (XIV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XlVa) or Formula (XlVb):
  • W is N; n is 1 or 2; p is 1 or 2; and q is 1 or 2. In some embodiments, W is N; n is 2; p is 2; and q is 2. . In some embodiments, W is CH; n is 1 or 2; p is 1 or 2; and q is 1 or 2. In some embodiments, W is CH; n is 2; p is 2; and q is 2.
  • a compound of Formula (I), (II), (III), (IV), (VIII), or (XIV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XlVa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (XlVb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • a compound of Formula (XlVa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XlVa-i):
  • W is N, CH, or CR A .
  • each R A is independently -F, -Cl, Ci- Ci alkyl, C 1 -C 4 fluoroalkyl, -OH, or -OR 10 .
  • each R A is independently -F, -Cl, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, -OH, or -OR 10 .
  • each R A is independently -F, -Cl, C 1 -C 7 alkyl, C 1 -C 4 fluoroalkyl, or -OR 10 . In some embodiments, each R A is independently -F, -Cl, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, or -OR 10 .
  • each R A is independently -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -C(CH 3 )3, -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH(CH 3 )2, - CH 2 C(CH 3 )3, - CH 2 CH 2 CH 2 CH 2 CH 3 , - CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2 C(CH 3 )3, - CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2 C(CH 3 )3, - CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2
  • each R A is independently -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, -CH 2 CH 2 CH 2 CH 3 , - CH 2 CH(CH 3 )2, -CH(CH 3 )(CH 2 CH 3 ), -C(CH 3 )3, -CH 2 F, -CHF 2 , -CF3, -OH, -OCH 3 , -OCH 2 CH 3 , - OCH(CH 3 ) 2 , or -OCF 3 .
  • each R A is independently -F, -Cl, -Br, -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), - C(CH 3 )3, -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH(CH 3 ) 2 , -CH 2 C(CH 3 ) 3 , - CH 2 CH 2 CH 2 CH 2 CH 3 , - CH 2 CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2 C(CH 3 )3, - CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2 C(CH 3 )3, - CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH(CH
  • each R A is independently -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, -CH 2 CH 2 CH 2 CH 3 , - CH 2 CH(CH 3 )2, -CH(CH 3 )(CH 2 CH 3 ), -C(CH 3 )3, -CH 2 F, -CHF 2 , -CF3, -OCH 3 , -OCH 2 CH 3 , - OCH(CH 3 ) 2 , or -OCF 3 .
  • each R A is independently halogen, C 1 -C 7 alkyl, - OH, or -OR 10 ; wherein each R 10 is independently C 1 -C 10 alkyl. In some embodiments, each R A is independently halogen, -OH, or -OR 10 ; wherein each R 10 is independently C 1 -C 10 alkyl. In some embodiments, each R A is independently halogen, C 1 -C 7 alkyl, or -OR 10 ; wherein each R 10 is independently C 1 -C 10 alkyl. In some embodiments, each R A is independently halogen or -OR 10 ; wherein each R 10 is independently C 1 -C 10 alkyl.
  • a compound of Formula (XlVa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XIVa-ii): or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof; wherein W is N or CH; X is halogen; and R 10 is C 1- C 10 alkyl.
  • the compound of Formula (I), (2), (3), (4), or (8), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (15):
  • Formula (15) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof wherein Y 2 is CH or N; p and q are each independently 1 or 2; W is N, CH, or CR A ; and n is 0, 1, or 2.
  • Y 2 is N.
  • Y 2 is CH.
  • p is 1 and q is 1.
  • p is 1 and q is 2.
  • p is 2 and q is 2.
  • n is 1 or 2.
  • n is 1.
  • n is 2.
  • W is N.
  • W is CH.
  • W is CR A .
  • W is N; n is 1 or 2; p is 1 or 2; and q is 1 or 2. In some embodiments, W is N; n is 2; p is 2; and q is 2. . In some embodiments, W is CH; n is 1 or 2; p is 1 or 2; and q is 1 or 2. In some embodiments, W is CH; n is 2; p is 2; and q is 2. In some embodiments, W is CH and Y 2 is N. In some embodiments, W is N and Y 2 is N.
  • the compound of Formula (I), (II), (III), (IV), or (VIII), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XV):
  • W is N; n is 2; p is 2; and q is 2. .
  • W is CH; n is 1 or 2; p is 1 or 2; and q is 1 or 2.
  • W is CH; n is 2; p is 2; and q is 2.
  • a compound of Formula (XV) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, is a compound of Formula (XV-i):
  • L 1 is *-O-CH 2 -, *-CH 2 -O-, *-NR 7 - CH 2 -, *-NR 7 -C(O)-, *-C(O)-NR 7 -, or *-C(O)-CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -CH 2 -; wherein * represents the connection to Ring B.
  • L 1 is *-NR 7 -C(O)- or *-C(O)-NR 7 -; wherein * represents the connection to Ring B.
  • L 1 is *-C(O)-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 - or *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-O-CH 2 -; wherein * represents the connection to Ring B. In some embodiments, L 1 is *-CH 2 -O-; wherein * represents the connection to Ring B. In some embodiments, R 7 is hydrogen or C 1- C 6 alkyl.
  • R 7 is hydrogen, -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , or — C(CH 3 )3.
  • R 7 is hydrogen or methyl. In some embodiments, R 7 is hydrogen.
  • a compound of Formula (I), (II), (III), (IV), (VIII), or (XV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XVa) or Formula (XVb):
  • W is N; n is 1 or 2; p is 1 or 2; and q is 1 or 2. In some embodiments, W is N; n is 2; p is 2; and q is 2. . In some embodiments, W is CH; n is 1 or 2; p is 1 or 2; and q is 1 or 2. In some embodiments, W is CH; n is 2; p is 2; and q is 2.
  • a compound of Formula (I), (II), (III), (IV), (VIII), or (XV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XVa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound is a compound of Formula (XVb), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • a compound of Formula (XVa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XVa-i):
  • W is N, CH, or CR A .
  • each R A is independently -F, -Cl, Ci- Ci alkyl, C 1 -C 4 fluoroalkyl, -OH, or -OR 10 .
  • each R A is independently -F, -Cl, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, -OH, or -OR 10 .
  • each R A is independently -F, -Cl, C 1 -C 7 alkyl, C 1 -C 4 fluoroalkyl, or -OR 10 . In some embodiments, each R A is independently -F, -Cl, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, or -OR 10 .
  • each R A is independently -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -C(CH 3 )3, -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH(CH 3 )2, - CH 2 C(CH 3 ) 3 , - CH 2 CH 2 CH 2 CH 2 CH 3 , - CH 2 CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2 C(CH 3 ) 3 , - CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2 C(CH 3 ) 3 , - CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH
  • each R A is independently -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , - CH 2 CH(CH 3 )2, -CH(CH 3 )(CH 2 CH 3 ), -C(CH 3 )3, -CH 2 F, -CHF 2 , -CF 3 , -OH, -OCH 3 , -OCH 2 CH 3 , - OCH(CH 3 ) 2 , or -OCF 3.
  • each R A is independently -F, -Cl, -Br, -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), - C(CH 3 ) 3 , -CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH(CH 3 ) 2 , -CH 2 C(CH 3 ) 3 , - CH 2 CH 2 CH 2 CH 2 CH 3 , - CH 2 CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2 C(CH 3 ) 3 , - CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH(CH 3 )2, -CH 2 CH 2 C(CH 3 ) 3 , - CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 , -CH
  • each R A is independently -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, -CH 2 CH 2 CH 2 CH 3 , - CH 2 CH(CH 3 )2, -CH(CH 3 )(CH 2 CH 3 ), -C(CH 3 )3, -CH 2 F, -CHF 2 , -CF3, -OCH 3 , -OCH 2 CH 3 , - OCH(CH 3 ) 2 , or -OCF 3 .
  • each R A is independently halogen, C 1 -C 7 alkyl, - OH, or -OR 10 ; wherein each R 10 is independently C 1 -C 10 alkyl. In some embodiments, each R A is independently C 1 -C 7 alkyl, -OH, or -OR 10 ; wherein each R 10 is independently C 1 -C 10 alkyl. In some embodiments, each R A is independently halogen, C 1 -C 7 alkyl, or -OR 10 ; wherein each R 10 is independently C 1 -C 10 alkyl. In some embodiments, each R A is independently C 1 -C 7 alkyl or - OR 10 ; wherein each R 10 is independently C 1 -C 10 alkyl.
  • a compound of Formula (XVa), or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound of Formula (XVa-ii):
  • R 5 is C 1- C 6 alkyl, C 3- C 6 cycloalkyl, phenyl, or -(C 1- C 6 alkyl)-phenyl; wherein each alkyl, cycloalkyl, and phenyl is independently unsubstituted or substituted with one, two, or three substituents selected from -F, -Cl, -OH, -O-(C 1- C 6 alkyl), C 1-
  • R 5 is C 1- C 6 alkyl. In some embodiments, R 5 is -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 )2, -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , or - CH(CH 3 )(CH 2 CH 3 ).
  • each R 6 is independently hydrogen, C 1 -C 6 alkyl, C 3- C 6 cycloalkyl, phenyl, or - (C 1 -C 6 alkyl )-phenyl; wherein each alkyl, cycloalkyl, and phenyl is independently unsubstituted or substituted with one, two, or three substituents selected from -F, -Cl, -OH, -O-(C 1-
  • each R 6 is independently hydrogen or C 1 -C 6 alkyl. In some embodiments, each R 6 is independently hydrogen, -CH 3 , -CH 2 CH 3 , - CH 2 CH 2 CH 3 , -CH(CH 3 )2, -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , or -CH(CH 3 )(CH 2 CH 3 ).
  • R 5 is C 1- C 6 alkyl, C 3- C 6 cycloalkyl, phenyl, or -(C 1- C
  • R 5 is C 1 -C 6 alkyl; and each R 6 is independently hydrogen or C 1 -C 6 alkyl.
  • R 5 is -CH 3 , - CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ;
  • each R 10 is independently C 1- C 6 alkyl; wherein each alkyl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, -OH, C 1- C 6 alkyl and C 1- C 6 hydroxyalkyl. In some embodiments, each R 10 is independently C 1- C 10 alkyl. In some embodiments, each R 10 is independently C 1- C 6 alkyl.
  • each R 11 is independently hydrogen, C 1- C 6 alkyl, or monocyclic heteroaryl; wherein each alkyl and heteroaryl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, -OH, C 1- C 6 alkyl and C 1- C 6 hydroxyalkyl.
  • each R 11 is independently hydrogen or C 1- C 6 alkyl; wherein each alkyl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, -OH, C 1- C 6 alkyl and C 1- C 6 hydroxyalkyl.
  • each R 11 is independently hydrogen or C 1- C 10 alkyl.
  • each R 11 is independently hydrogen or C 1- C 6 alkyl.
  • two R 11 on the same nitrogen atom are taken together with the nitrogen to which they are attached to form a 3- to 6-membered N-heterocycloalkyl ; wherein the heterocycloalkyl is unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, -OH, C 1- C 6 alkyl, and C 1- C 6 hydroxyalkyl.
  • two R 11 on the same nitrogen atom are taken together with the nitrogen to which they are attached to form a 3- to 6-membered N-h eterocy cloalkyl.
  • each R 10 is independently C 1- C 6 alkyl; wherein each alkyl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, -OH, C 1- C 6 alkyl and C 1- C 6 hydroxyalkyl; and each R 11 is independently hydrogen, C 1- C 6 alkyl, or monocyclic heteroaryl; wherein each alkyl and heteroaryl is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, -OH, C 1- C 6 alkyl and C 1- C 6 hydroxyalkyl; or two R 11 on the same nitrogen atom are taken together with the nitrogen to which they are attached to form a 3- to 6-membered N-heterocycloalkyl; wherein the heterocycloalkyl is unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, -OH
  • the compound of Formula (I) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound selected from: or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof.
  • the compound of Formula (I) or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is a compound selected from:
  • the compounds described herein exist as “geometric isomers.” In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti,
  • Z isomers as well as the corresponding mixtures thereof. In some situations, compounds exist as tautomers.
  • a “tautomer” refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible.
  • the compounds presented herein exist as tautomers. In circumstances where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include: [00205] In some situations, the compounds described herein possess one or more chiral centers and each center exists in the ( R )- configuration or (S)- configuration.
  • the compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof.
  • mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.
  • the compounds described herein are prepared as optically pure enantiomers by chiral chromatographic resolution of the racemic mixture.
  • the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
  • dissociable complexes are preferred (e.g., crystalline diastereomeric salts).
  • the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities.
  • the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • positional isomer refers to structural isomers around a central ring, such as ortho-, meta-, and para- isomers around a benzene ring.
  • N- oxides if appropriate
  • crystalline forms also known as polymorphs
  • pharmaceutically acceptable salts of compounds described herein as well as active metabolites of these compounds having the same type of activity.
  • “Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • a pharmaceutically acceptable salt of any one of the compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
  • Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, pheny1-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • acetic acid trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
  • Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
  • salts of amino acids such as arginates, gluconates, and galacturonates (see, for example, Berge S.M. et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66: 1- 19 (1997).
  • Acid addition salts of basic compounds are prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt.
  • “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N- dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • prodrug is meant to indicate a compound that is, in some embodiments, converted under physiological conditions or by solvolysis to an active compound described herein.
  • prodrug refers to a precursor of an active compound that is pharmaceutically acceptable.
  • a prodrug is typically inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis.
  • the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
  • prodrugs are also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of an active compound, as described herein are prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo , to the parent active compound.
  • Prodrugs include compounds wherein a hydroxy, amino, carboxy, or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino, free carboxy, or free mercapto group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amine functional groups in the active compounds and the like.
  • solvates refers to a composition of matter that is the solvent addition form.
  • solvates contain either stoichiometric or non- stoichiometric amounts of a solvent, and are formed during the process of making with pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • “Hydrates” are formed when the solvent is water, or “alcoholates” are formed when the solvent is alcohol.
  • Solvates of compounds described herein are conveniently prepared or formed during the processes described herein. The compounds provided herein optionally exist in either unsolvated as well as solvated forms.
  • the compounds disclosed herein are used in different enriched isotopic forms, e.g., enriched in the content of 2 H, 1 H, 11 C, 13 C and/or 14 C.
  • the compound is deuterated in at least one position.
  • deuterated forms can be made by the procedure described in U.S. Patent Nos. 5,846,514 and 6,334,997. As described in U.S. Patent Nos. 5,846,514 and 6,334,997, deuteration can improve the metabolic stability and or efficacy, thus increasing the duration of action of drugs.
  • structures depicted herein are intended to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon are within the scope of the present disclosure.
  • the compounds of the present disclosure optionally contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds.
  • the compounds may be labeled with isotopes, such as for example, deuterium ( 2 H), tritium ( 1 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). Isotopic substitution with 2 H, 1 H, 11 C, 13 C, 14 C, 15 C, 12 N,
  • the compounds disclosed herein have some or all of the 1 H atoms replaced with 2 H atoms.
  • the methods of synthesis for deuterium-containing compounds are known in the art.
  • deuterium substituted compounds are synthesized using various methods such as described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In: Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organ ometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Cl 2 em., 1981, 64(1-2), 9-32.
  • the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
  • the compounds described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, as described herein are substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.
  • a pharmaceutical composition comprising a GPR40 agonist described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable excipient.
  • the GPR40 agonist is combined with a pharmaceutically suitable (or acceptable) carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration, e.g., oral administration, and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).
  • composition comprising a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable excipient.
  • aqueous and non-aqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate and cyclodextrins.
  • Proper fluidity is maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is administered in combination with a TGR5 agonist, a GPR119 agonist, an SSTR5 antagonist, an SSTR5 inverse agonist, a CCK1 agonist, aPDE4 inhibitor, a DPP-4 inhibitor, a GLP-1 receptor agonist, a ghrelin G-acyl transferase (GOAT) inhibitor, metformin, or combinations thereof.
  • the pharmaceutical composition further comprises one or more anti -diabetic agents. In certain embodiments, the pharmaceutical composition further comprises one or more anti-obesity agents. In certain embodiments, the pharmaceutical composition further comprises one or more agents to treat nutritional disorders.
  • TGR5 agonist to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, include: INT-777, XL-475, SRX-1374, RDX-8940, RDX-98940, SB-756050, and those disclosed in WO-2008091540, WO-2010059853, WO-2011071565, WO-2018005801, WO-2010014739, WO-2018005794, WO-2016054208, WO-2015160772, WO-2013096771, WO-2008067222, WO-2008067219, WO-2009026241, WO-2010016846,
  • Examples of a GPR119 agonist to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof include: DS-8500a, HD-2355, LC34AD3, PSN-491, HM-47000, PSN-821, MBX-2982, GSK- 1292263, APD597, DA-1241, and those described in WO-2009141238, WO-2010008739, WO-2011008663, WO-2010013849, WO-2012046792, WO-2012117996, WO-2010128414, WO-2011025006, WO-2012046249, WO-2009106565, WO-2011147951, WO-2011127106, WO-2012025811, WO-2011138427, WO-2011140161, WO-2011061679, WO-2017175066, WO-2017175068, WO-2015080446, WO-20
  • Examples of a SSTR5 antagonist or inverse agonist to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, include those described in: WO-03104816, WO-2009050309, WO- 2015052910, WO-2011146324, WO-2006128803, WO-2010056717, WO-2012024183, and WO-2016205032.
  • Examples of a CCK1 agonist to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof include: A-70874, A-71378, A-71623, A-74498, CE-326597, GI-248573, GSKI-181771X, NN-9056,
  • Examples of a PDE4 inhibitor to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, include: apremilast, cilomilast, crisaborole, diazepam, luteolin, piclamilast, and roflumilast.
  • Examples of a DPP-4 inhibitor to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof include: sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, teneligliptin, alogliptin, trelagliptin, omarigliptin, evogliptin, gosogliptin, and dutogliptin.
  • Examples of a GLP-1 receptor agonist to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, include: albiglutide, dulaglutide, exenatide, extended-release exenatide, liraglutide, lixisenatide, and semaglutide.
  • Examples of a GOAT inhibitors to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof include: T-3525770 (RM-852), GLWL-01, BOS-704, and those described in US- 08013015, US-09340578, WO-2019149959, US-20170056373, WO-2018035079, WO- 2016044467, WO-2010039461, WO-2018024653, WO-2019149660, WO-2019149659, WO- 2015073281, WO-2019149658, WO-2016168225, WO-2016168222, WO-2019149657, WO- 2013125732, and WO-2019152889.
  • anti-diabetic agents examples include: GLP-1 receptor agonists such as exenatide, liraglutide, taspoglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, OWL833 and ORMD 0901; SGLT2 inhibitors such as dapagliflozin, canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin, sergliflozin, sotagliflozin, and tofogliflozin; biguinides such as metformin; insulin and insulin analogs.
  • GLP-1 receptor agonists such as exenatide, liraglutide, taspoglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, OWL833 and ORMD 0901
  • SGLT2 inhibitors such as
  • anti-obesity agents examples include: GLP-1 receptor agonists such as liraglutide, semaglutide; SGLT1/2 inhibitors such as LIK066, pramlintide and other amylin analogs such as AM-833, AC2307, and BI 473494; PYY analogs such as NN-9747, NN-9748, AC-162352, AC-163954, GT-001, GT-002, GT-003, and RHS-08; GIP receptor agonists such as APD-668 and APD-597; GLP-1/GIP co- agonists such as tirzepatide (LY329176), BHM-089, LBT-6030, CT-868, SCO-094, NNC-0090- 2746, RG-7685, NN-9709, and SAR-438335; GLP-
  • agents for nutritional disorders to be used in combination with a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, include: GLP-2 receptor agonists such as tedaglutide, glepaglutide (ZP1848), elsiglutide (ZP1846), apraglutide (FE 203799), HM-15912, NB-1002, GX-G8, PE-0503, SAN- 134, and those described in WO-2011050174, WO-2012028602, WO-2013164484, WO- 2019040399, WO-2018142363, WO-2019090209, WO-2006117565, WO-2019086559, WO- 2017002786, WO-2010042145, WO-2008056155, WO-2007067828, WO-2018229252, WO- 2013040093, WO-2002066511, WO-2005067368, WO-2009
  • the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant (i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
  • an adjuvant i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced.
  • the benefit experienced by a patient is increased by administering one of the compounds described herein with another agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • a compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof is co-administered with one or more additional therapeutic agents, wherein the compound described herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, and the additional therapeutic agent(s) modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.
  • the additional therapeutic agent(s) is a TGR5 agonist, a GPR119 agonist, an SSTR5 antagonist, an SSTR5 inverse agonist, a CCK1 agonist, aPDE4 inhibitor, a DPP-4 inhibitor, a GOAT inhibitor, a GLP-1 receptor agonist, metformin, or combinations thereof.
  • the additional therapeutic agent is an anti-diabetic agent.
  • the additional therapeutic agent is an anti-obesity agent.
  • the additional therapeutic agent is an agent to treat nutritional disorders.
  • the multiple therapeutic agents are administered in any order or even simultaneously. If administration is simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms (e.g., as a single pill or as two separate pills).
  • the compounds described herein, or pharmaceutically acceptable salts, solvates, stereoisomers, or prodrugs thereof, as well as combination therapies, are administered before, during or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound varies.
  • the compounds described herein are used as a prophylactic and are administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition.
  • the compounds and compositions are administered to a subject during or as soon as possible after the onset of the symptoms.
  • a compound described herein is administered as soon as is practicable after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease.
  • a compound described herein, or a pharmaceutically acceptable salt thereof is administered in combination with anti-inflammatory agent, anti-cancer agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, hormone blocking therapy, radiation therapy, monoclonal antibodies, or combinations thereof.
  • Step 1 (3-(benzyloxy)phenyl)(cyclopropyl)methanol (A-1):
  • Step 3 1-(benzyloxy)-3-(1-cyclopropylvinyl)benzene (A-3):
  • Step 4 2-(3-(benzyloxy)phenyl)-2-cyclopropylethanol (A-4):
  • Step 5 (S)-2-(3-(benzyloxy)phenyl)-2-cyclopropylethanol (A-5):
  • Compound A-4 (9.1 g) was separated by SFC (column: DAICEL CHIRALPAK AD (250mm x 50 mm, 10 um); mobile phase: [A: CO 2 , B: 0.1%NH 4 OH in MeOH]; B%: 45%-45%) to give A-5 (4.2 g, 45% yield) as a colourless oil.
  • t R 1.767 min on SFC.
  • Step 6 (S)-1-(benzyloxy)-3-(1-cyclopropy1-2-iodoethyl)benzene (A-6):
  • Step 7 ethyl ((S)-2-(3-(benzyloxy)phenyl)-2-cyclopropylethyl)(methyl)phosphinate (A-7):
  • Racemic R,S-Int-A was prepared following the procedures outlined in Example 1 Steps 6 to 8 starting from A-4.
  • Step 1 2-(benzyloxy)-4-bromopyridine (B-1):
  • Step 3 2-(benzyloxy)-4-(1-cyclopropylvinyl)pyridine (B-3):
  • Step 5 (S)-2-(2-(benzyloxy)pyridin-4-yl)-2-cyclopropylethanol (B-5):
  • Compound B-4 (38 g) was purified by SFC (column: DAICEL CHIRALPAK AY (250 mmx50 mm, 10 um); mobile phase: [A: CO 2 , B: 0.1% NH 4 OH in IP A]; B%: 20%) to give B-5 (16 g, 42% yield) as a yellow oil.
  • t R 1.797 min on SFC.
  • Step 6 (S)-2-(benzyloxy)-4-(1-cyclopropy1-2-iodoethyl)pyridine (B-6):
  • Step 7 ethyl ((S)-2-(2-(benzyloxy)pyridin-4-yl)-2- cyclopropylethyl)(methyl)phosphinate (B-7) [00277] A solution of B-6 (4.0 g, 11 mmol) in diethyl methylphosphonite (29 g, 0.21 mol) was stirred at 130 °C for 6 hours. The reaction mixture was concentrated under reduced pressure to give a residue.
  • Step 8 ethyl ((S)-2-cyclopropy1-2-(2-hydroxypyridin-4- yl)ethyl)(methyl)phosphinate (Int-B)
  • Step 1 1-(benzyloxy)-3-(prop-1-en-2-yl)benzene (C-1):
  • Step 3 1-(benzyloxy)-3-(1-iodopropan-2-yl)benzene (C-3):
  • Step 4 ethyl (2-(3-(benzyloxy)phenyl)propyl)(methyl)phosphinate (C-4):
  • Step 5 ethyl (2-(3-hydroxyphenyl)propyl)(methyl)phosphinate (Int-C):
  • Step 1 2-(benzyloxy)-4-bromopyridine (D-1):
  • Step 2 2-(benzyloxy)-4-(prop-1-en-2-yl)pyridine (D-2):
  • Step 3 2-(2-(benzyloxy)pyridin-4-yl)propan-1-ol (D-3):
  • Step 5 2-(2-(benzyloxy)pyridin-4-yl)propyl 4-methylbenzenesulfonate (D-4):
  • Step 7 ethyl (2-(2-hydroxypyridin-4-yl)propyl)(methyl)phosphinate (Int-D):
  • Step 1 methyl 4-(((perfluorobutyl)sulfonyl)oxy)cyclohex-3-enecarboxylate (E-1):
  • Step 2 methyl 2'-fluoro-5'-methoxy-2,3,4,5-tetrahydro-[1,1-biphenyl]-4-carboxylate (E-2):
  • Step 4 (trans)- methyl 4-(2-fluoro-5-methoxyphenyl)cyclohexanecarboxylate (E-4):
  • Step 5 ((trans)-4-(2-fluoro-5-methoxyphenyl)cyclohexyl)methanol (E-5):
  • Step 6 ((trans)-4-(2-fluoro-5-methoxyphenyl)cyclohexyl (methyl methanesulfonate
  • Step 1 3,3-dimethylbutyl methanesulfonate (F-1):
  • Step 2 (3,3-dimethylbutyl)triphenylphosphonium methanesulfonate (F-2): [00317] A mixture of F-1 (3.1 g, 17 mmol, 1 eq) and PPh3 (4.5 g, 17 mmol, 1 eq) was stirred at 120 °C for 16 hr. The reaction was cooled to room temperature. The reaction mixture was purified by recrystallization from petroleum ether solvent (20 mL) to give F-2 (6 g, crude) as an off-white solid.
  • Step 3 methyl 1-(2-formy1-5-methoxyphenyl)piperidine-4-carboxylate (F-3):
  • Step 4 (E)-methyl 1-(2-(4,4-dimethylpent-1-en-1-yl)-5-methoxyphenyl)piperidine- 4-carboxylate (F-4):
  • reaction mixture was quenched by addition of saturated aqueous NH 4 CI (10 mL) at 0 °C, diluted with water (50 mL) and extracted with EA (50 mL x 3). The combined organic layers were washed with saturated brine (150 mL x 2), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
  • Step 5 methyl 1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidine-4-carboxylate (F-5):
  • Step 1 (3-(benzyloxy)phenyl)(cyclopropyl)methanol (1-1):
  • Step 4 2-(3-(benzyloxy)phenyl)-2-cyclopropylethanol (1-4):
  • Step 5 1-(benzyloxy)-3-(1-cyclopropy1-2-iodoethyl)benzene (1-5):
  • Step 6 ⁇ imethyl (2-(3-(benzyloxy)phenyl)-2-cyclopropylethyl)phosphonate (1-6):
  • Step 8 ⁇ imethyl (2-cyclopropyl-2-(3-(((trans)-4-(2-fluoro-5 methoxyphenyl)cyclohexyl)methoxy)phenyl)ethyl)phosphonate (1-8):
  • Step 9 methyl hydrogen (2-cyclopropy1-2-(3-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)phenyl)ethyl)phosphonate (Compound 1):
  • Step 1 3-(1-cyclopropy1-2-hydroxyethyl)phenol (3-1): [00346] To a solution of 1-4 (1.1 g, 4.1 mmol, 1.0 eq) in THF (10 mL) was added Pd/C (0.21 g, 0.41 mmol, 10% purity, 0.10 eq) under N2. The suspension was degassed under vacuum and purged with H 2 several times. The mixture was stirred under H 2 (15 psi) at 50 °C for 2 hrs.
  • Step 2 2-cyclopropy1-2-(3-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)phenyl)ethanol (3-2):
  • Step 3 2-cyclopropy1-2-(3-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)phenyl)ethyl methanesulfonate (3-3):
  • Step 4 2-((trans , )-4-((3-(1-cyclopropy1-2-iodoethyl)phenoxy)methyl)cyclohexyl)-1- fluoro-4-methoxybenzene (3-4): [00352] To a solution of 3-3 (0.34 g, 0.71 mmol, 1.0 eq) in acetone (5.0 mL) was added Nal (0.53 g, 3.6 mmol, 5.0 eq). The mixture was stirred at 60 °C for 12 hrs. The mixture was extracted with ethyl acetate (50 mL x 2).
  • Step 5 2-cyclopropy1-2-(3-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)phenyl)ethanesulfonic acid (Compound 3):
  • Step 1 ⁇ imethyl (1-(3-(benzyloxy)phenyl)-1-cyclopropylpropan-2-yl)phosphonate
  • Step 2 dimethyl (1 -cyclopropy1- 1 -(3 -hydroxyphenyl)propan-2-yl)phosphonate (4-
  • Step 3 dimethyl (1-cyclopropy1-1-(3-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)phenyl)propan-2-yl)phosphonate (4-3):
  • Step 4 (1-cyclopropy1-1-(3-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)phenyl)propan-2-yl)phosphonic acid (Compound 4):
  • Step 7 ethyl (2-cyclopropyl-2-(3-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)phenyl)ethyl)(methyl)phosphinate (5-1):
  • SFC column: DAICEL CHIRALPAK AS (250x30mmx10um); mobile phase: A: [CO 2 ; B: 0.1% NH 4 OH in E t OH]; B%: 50%
  • Step 8 (2-cyclopropy1-2-(3-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)phenyl)ethyl)(methyl)phosphinic acid (Compounds 5, 6, 7, 8):
  • Step 1 2-((trans)-4-(chlororn ethyl )cyclohexyl)- l -fluoro-4-methoxybenzene (9-1):
  • Step 2 ethyl ((S)-2-cyclopropy1-2-(2-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)pyridin-4-yl)ethyl)(methyl)phosphinate (9-2):
  • Step 3 ((S)-2-cyclopropy1-2-(2-(((trans)-4-(2-fluoro-5- methoxyphenyl)cyclohexyl)methoxy)pyridin-4-yl)ethyl)(methyl)phosphinic acid (Compound 9):
  • Example 13 Preparation of ((S)-2-cyclopropy1-2-(3-((1-(2-(4,4-dimethylpentyl)-5- methoxyphenyl)piperidin-4-yl)methoxy)phenyl)ethyl)(methyl)phosphinic acid (Compound 10) [00380] Step 1: ethyl ((S)-2-cyclopropy1-2-(3-((1-(2-(4,4-dimethylpentyl)-5- methoxyphenyl)piperidin-4-yl)methoxy)phenyl)ethyl)(methyl)phosphinate (10-1):
  • Step 2 ((S)-2-cyclopropy1-2-(3-((1-(2-(4,4-dimethylpentyl)-5- methoxyphenyl)piperidin-4-yl)methoxy)phenyl)ethyl)(methyl)phosphinic acid (Compound
  • Step 1 4-(bromomethyl)-1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidine
  • Step 2 ethyl ((S)-2-cyclopropy1-2-(2-((1-(2-(4,4-dimethylpentyl)-5- methoxyphenyl)piperidin-4-yl)methoxy)pyridin-4-yl)ethyl)(methyl)phosphinate (11-2):
  • Step 3 ((S)-2-cyclopropy1-2-(2-((1-(2-(4,4-dimethylpentyl)-5- methoxyphenyl)piperidin-4-yl)methoxy)pyridin-4-yl)ethyl)(methyl)phosphinic acid (Compound 11):
  • Step 1 ethyl ((R)-2-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propyl)(methyl)phosphinate (14-1):
  • Step 2 ((R)-2-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propyl)(methyl)phosphinic acid (Compound 14):
  • Step 1 ethyl ((S)-2-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propyl)(methyl)phosphinate (15-1):
  • Step 2 ((S)-2-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propyl)(methyl)phosphinic acid) (Compound 15):
  • Step 1 2-(3-(benzyloxy)phenyl)ethan-1-ol (16-1):
  • Step 2 1-(benzyloxy)-3-(2-iodoethyl)benzene (16-2):
  • Step 3 ⁇ iethyl (3-(benzyloxy)phenethyl)phosphonate (16-3):
  • Step 4 ⁇ iethyl (1-(3-(benzyloxy)phenyl)propan-2-yl)phosphonate (16-4):
  • reaction mixture was quenched with saturated aqueous NH 4 C1 solution (80 mL) with stirring at 0 °C and extracted with ethyl acetate (30 mL x 3).
  • the combined organic layer was concentrated to give a residue that was then purified by reversed-phase HPLC (column: Phenomenex Luna C18 250 x 50 mm x 10 um; mobile phase: [A: water (0.1% FA, v/v), B: can]; B%: 42%-72% gradient over 30 min) to give 16-4 (0.31 g, 23% yield) as a brown oil.
  • Step 5 ⁇ iethyl (1-(3-hydroxyphenyl)propan-2-yl)phosphonate (16-5):
  • Step 6 ⁇ iethyl (1-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propan-2-yl)phosphonate (16-6):
  • Step 7 (1-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propan-2-yl)phosphonic acid (Compound 16):
  • Step 1 (R)-1-(3-(benzyloxy)phenyl)butan-2-ol (17-1):
  • Step 2 (R)-1-(benzyloxy)-3-(2-iodobutyl)benzene (17-2):
  • Step 3 ethyl ((R)-1-(3-(benzyloxy)phenyl)butan-2-yl)(methyl)phosphinate (17-3):
  • Step 5 ethyl ((R)-1-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)butan-2-yl)(methyl)phosphinate (17-5):
  • Step 1 (S)-1-(3-(benzyloxy)phenyl)butan-2-ol (18-1):
  • Step 2 (S)-1-(benzyloxy)-3-(2-iodobutyl)benzene (18-2):
  • Step 3 ethyl ((S)-1-(3-(benzyloxy)phenyl)butan-2-yl)(methyl)phosphinate (18-3):
  • Step 4 ethyl ((S)-1-(3-hydroxyphenyl)butan-2-yl)(methyl)phosphinate (18-4):
  • Step 5 ethyl ((S)-1-(3-hydroxyphenyl)butan-2-yl)(methyl)phosphinate (18-4):
  • Step 6 ((S)-1-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)butan-2-yl)(methyl)phosphinic acid (Compound 18):
  • Step 1 ⁇ iethyl (S)-(2-(3-(benzyloxy)phenyl)propyl)phosphonate (19-1):
  • Step 2 ⁇ iethyl (S)-(2-(3-hydroxyphenyl)propyl)phosphonate (19-2):
  • Step 3 ⁇ iethyl (S)-(2-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propyl)phosphonate (19-3):
  • Step 4 (S)-(2-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propyl)phosphonic acid (Compound 19):
  • Step 1 ⁇ iethyl (R)-(2-(3-(benzyloxy)phenyl)propyl)phosphonate (20-1):
  • Step 2 ⁇ iethyl (R)-(2-(3-hydroxyphenyl)propyl)phosphonate (20-2):
  • Step 3 ⁇ iethyl (R)-(2-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propyl)phosphonate (20-3):
  • Step 4 (R)-(2-(3-((1-(2-(4,4-dimethylpentyl)-5-methoxyphenyl)piperidin-4- yl)methoxy)phenyl)propyl)phosphonic acid (Compound 20):
  • CHO-K1 cells expressing human GPR40 were purchased from DiscoverX (95- 1005C2).
  • HEK293 cells expressing mouse FFAR1 were prepared using a mouse FFAR1 carrying plasmid purchased from OriGene Technologies (MR222997). The cells were transfected using Lipofectamine 2000 using manufacturer instructions and stable cell line was established from a single cell using geneticine selection. Assay ready frozen (ARF) cells were prepared and used throughout the study.
  • the assay was performed in a 384-well plate format using IP1 assay kit from Cis- Bio.
  • ARF cells expressing FFAR1 (mouse and human) were thawed, washed and then plated in the appropriate medium (F12 based medium for CHO hFFARl and DMEM based medium for HEK293 mFFARl - both were supplemented with 10% FBS and penicillin/streptomycin).
  • 20 ⁇ L of 3.5x10 5 cells/mL were plated on a Poly D-Lysine coated 384-well white plate. The cells were then incubated for 16 hr at 37 °C / 5 % CO 2 .
  • the medium was removed and 15 ⁇ L of stimulation buffer containing the test compounds was added to the cells.
  • the plates were then incubated for 90 min at 37 °C / 5 % CO 2 .
  • 5 ⁇ L of detection buffer (prepared as described in the IP-one kit) was added to each well and the plates were incubated at RT for lhr.
  • RT-FRET was measured using ClarioSTAR plate reader, calculating the ratio between emissions at 665 nm and 620 nm (HTRF ratio).
  • HTRF ratio for positive (Max) and negative (Min) controls were used to normalize HTRF data and generate values for % activity.
  • EC 50 and Max activity values were determined using a standard 4-parameter fit.
  • Example A-2 In Vivo Plasma Levels in Mice
  • mice 10-12 weeks old were dosed with test article (30 mg/kg) or vehicle by oral gavage. Animals were euthanized with carbon dioxide at 2 h or 5 h post dose. Blood was collected for measurement of plasma concentrations of test article. Unbound exposure was calculated by multiplying the measured total exposure by the free fraction as assessed from plasma protein binding.
  • Plasma protein binding to isotonic phosphate buffer (PBS) containing 10% C57 BL/6 mouse plasma was determined using equilibrium dialysis of plasma spiked with test article (2 mM) against a dialysis buffer (100 mM sodium phosphate and 150 mM NaCl). At the end of the dialysis (4 hr), aliquots of the plasma and buffer were processed by protein precipitation for LC- MS/MS analysis to quantitate the test article.
  • PBS isotonic phosphate buffer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2021/019975 2020-02-28 2021-02-26 Gpr40 agonists Ceased WO2021174048A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2022010548A MX2022010548A (es) 2020-02-28 2021-02-26 Agonistas de gpr40.
CN202180031976.3A CN115667277A (zh) 2020-02-28 2021-02-26 Gpr40激动剂
EP21759945.5A EP4110788A4 (en) 2020-02-28 2021-02-26 Gpr40 agonists
PH1/2022/552277A PH12022552277A1 (en) 2020-02-28 2021-02-26 Gpr40 agonists
KR1020227033245A KR20220149558A (ko) 2020-02-28 2021-02-26 Gpr40 작용제
JP2022551554A JP7745559B2 (ja) 2020-02-28 2021-02-26 Ｇｐｒ４０アゴニスト
BR112022017039A BR112022017039A2 (pt) 2020-02-28 2021-02-26 Agonistas de gpr40
CA3173731A CA3173731A1 (en) 2020-02-28 2021-02-26 Gpr40 agonists
IL295825A IL295825A (en) 2020-02-28 2021-02-26 gpr40 agonists
AU2021228729A AU2021228729A1 (en) 2020-02-28 2021-02-26 GPR40 agonists
US17/745,126 US12264171B2 (en) 2020-02-28 2022-05-16 GPR40 agonists
US19/042,316 US20250276989A1 (en) 2020-02-28 2025-01-31 Gpr40 agonists

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062983438P 2020-02-28 2020-02-28
US62/983,438 2020-02-28
US202063076113P 2020-09-09 2020-09-09
US63/076,113 2020-09-09
US202063117074P 2020-11-23 2020-11-23
US63/117,074 2020-11-23
US202163147980P 2021-02-10 2021-02-10
US63/147,980 2021-02-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/745,126 Continuation US12264171B2 (en) 2020-02-28 2022-05-16 GPR40 agonists

Publications (1)

Publication Number Publication Date
WO2021174048A1 true WO2021174048A1 (en) 2021-09-02

Family

ID=77490355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/019975 Ceased WO2021174048A1 (en) 2020-02-28 2021-02-26 Gpr40 agonists

Country Status (15)

Country Link
US (2) US12264171B2 (https=)
EP (1) EP4110788A4 (https=)
JP (1) JP7745559B2 (https=)
KR (1) KR20220149558A (https=)
CN (1) CN115667277A (https=)
AU (1) AU2021228729A1 (https=)
BR (1) BR112022017039A2 (https=)
CA (1) CA3173731A1 (https=)
CL (1) CL2022002323A1 (https=)
IL (1) IL295825A (https=)
MX (1) MX2022010548A (https=)
PH (1) PH12022552277A1 (https=)
TW (1) TW202140440A (https=)
UY (1) UY39107A (https=)
WO (1) WO2021174048A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
WO2023250323A1 (en) * 2022-06-24 2023-12-28 Kallyope, Inc. Gpr119 and gpr40 agonist combination therapies for gut-brain axis disorders
US12018015B2 (en) 2021-06-18 2024-06-25 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
US12264171B2 (en) 2020-02-28 2025-04-01 Kallyope, Inc. GPR40 agonists
WO2025136929A1 (en) * 2023-12-19 2025-06-26 Kallyope, Inc. Gpr40 agonists
WO2025137315A1 (en) * 2023-12-22 2025-06-26 Kallyope, Inc. Combination therapy for treatment of metabolic disease
WO2025137310A1 (en) * 2023-12-22 2025-06-26 Kallyope, Inc. Crystalline gpr40 agonist and methods of making
US12428427B2 (en) 2021-12-16 2025-09-30 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025165758A1 (en) * 2024-01-31 2025-08-07 The Regents Of The University Of California Combination formulations and methods for treating severe metabolic disorders or diseases

Citations (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014066A1 (en) 1992-01-09 1993-07-22 James Black Foundation Limited Amino acid derivatives with anticholecystokinin activity
WO1993016982A1 (en) 1992-02-20 1993-09-02 James Black Foundation Limited Bicyclo[2.2.2.]octane derivatives as cholestocystokinin inhibitors
WO1994024151A1 (en) 1993-04-15 1994-10-27 Glaxo Inc. 1,5 benzodiazepine derivatives having cck and/or gastrin antagonistic activity
WO1995028399A1 (en) 1994-04-15 1995-10-26 Glaxo Wellcome Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
WO1995028419A1 (en) 1994-04-14 1995-10-26 Glaxo Wellcome Inc. Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
WO1995028391A1 (en) 1994-04-15 1995-10-26 Glaxo Wellcome Inc. Cck or gastrin modulating 1,5 benzodiazepines derivatives
WO1996011940A1 (en) 1994-10-14 1996-04-25 Glaxo Wellcome Inc. Acyl amino acetamide derivatives with agonist activity for cck-a receptors
WO1996011691A1 (en) 1994-10-14 1996-04-25 Glaxo Wellcome Inc. Use of 1,5-benzodiazepine derivatives for the control of gastric emptying in patients with non-insulin dependent diabetes mellitus
WO1996032414A1 (en) 1995-04-14 1996-10-17 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO1997039031A1 (en) 1996-04-12 1997-10-23 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
WO1998051686A1 (fr) 1997-05-13 1998-11-19 Sanofi-Synthelabo N-triazolyl-2-indolecarboxamides et leur utilisation comme agonistes de cck-a
US5846514A (en) 1994-03-25 1998-12-08 Isotechnika, Inc. Enhancement of the efficacy of nifedipine by deuteration
WO1999015525A1 (fr) 1997-09-19 1999-04-01 Sanofi-Synthelabo Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant
WO2000068209A2 (en) 1999-05-06 2000-11-16 Glaxo Group Limited 1,5-benzodiazepine derivatives as cck-a receptor agonists
WO2001077108A1 (en) 2000-04-07 2001-10-18 Sanofi-Synthelabo Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO2002034743A1 (en) 2000-10-26 2002-05-02 Sanofi-Synthelabo Triazole derivatives and pharmaceutical compositions comprising them
WO2002044150A1 (en) 2000-11-28 2002-06-06 Sanofi-Synthelabo Chemical process and new intermediates
WO2002066511A2 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
WO2003104816A1 (en) 2002-06-07 2003-12-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (sstr5)
WO2005035793A2 (en) 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
WO2005067368A2 (en) 2003-11-21 2005-07-28 Nps Allelix Corp. Production of glucagon like peptide 2 and analogs
WO2005116034A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
US20060177438A1 (en) 2005-02-08 2006-08-10 New England Medical Center Methods of altering absorption of hydrophobic compounds
WO2006117565A2 (en) 2005-05-04 2006-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
WO2006128803A1 (en) 2005-06-02 2006-12-07 F. Hoffmann-La Roche Ag Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
WO2007003962A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007067828A2 (en) 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
WO2007120688A2 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2007120689A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2007120655A2 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2008025798A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders
WO2008028117A2 (en) 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008056155A1 (en) 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
WO2008067222A1 (en) 2006-11-28 2008-06-05 Kalypsys, Inc. Heterocyclic modulators of tgr5
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
WO2008083238A2 (en) 2006-12-28 2008-07-10 Metabolex Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2008091631A1 (en) 2007-01-26 2008-07-31 Merck & Co., Inc. Substituted aminopyrimidines as cholecystokinin-1 receptor modulators
WO2008091540A2 (en) 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008097428A2 (en) 2007-02-02 2008-08-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2008109702A1 (en) 2007-03-08 2008-09-12 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
WO2008137436A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
WO2009012275A1 (en) 2007-07-17 2009-01-22 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
WO2009026241A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5
WO2009050309A1 (es) 2007-10-17 2009-04-23 Universidad De Cordoba Isoformas del receptor de somatostatina humano tipo 5 producidas por procesamiento alternativo y parejas de oligonucleótidos para su detección por pcr
WO2009105717A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009105722A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009105715A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2009119733A1 (ja) 2008-03-26 2009-10-01 パナソニック電工株式会社 発光装置
WO2009123992A1 (en) 2008-03-31 2009-10-08 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
WO2009126535A1 (en) 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009143049A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2009141238A1 (en) 2008-05-19 2009-11-26 F. Hoffmann-La Roche Ag Gpr119 receptor agonists
WO2010006191A1 (en) 2008-07-11 2010-01-14 Irm Llc 4-phenoxymethylpiperidines as modulators of gpr119 activity
WO2010008851A1 (en) 2008-06-24 2010-01-21 Berger Terry A A compressible fluid pumping system
WO2010009183A1 (en) 2008-07-16 2010-01-21 Bristol-Myers Squibb Company Pyridone and pyridazone analogues as gpr119 modulators
WO2010008739A2 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
WO2010013849A1 (ja) 2008-08-01 2010-02-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2010014739A2 (en) 2008-07-29 2010-02-04 Kalypsys, Inc. Heterocyclic modulators of tgr5
WO2010016846A1 (en) 2008-08-08 2010-02-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2010039461A2 (en) 2008-10-03 2010-04-08 The Johns Hopkins University Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes
WO2010042145A1 (en) 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2010059859A1 (en) 2008-11-19 2010-05-27 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2010059853A1 (en) 2008-11-19 2010-05-27 Intercept Pharmaceuticals, Inc. Tgr5 modulators and method of use thereof
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
WO2010093845A1 (en) 2009-02-12 2010-08-19 Exelixis, Inc. Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
WO2011008663A1 (en) 2009-07-15 2011-01-20 Eli Lilly And Company Gpr119 agonists
WO2011025006A1 (ja) 2009-08-31 2011-03-03 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011044001A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011050174A1 (en) 2009-10-23 2011-04-28 Ferring B.V. Peptidic glp-2 agonists
WO2011061679A1 (en) 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
WO2011071565A1 (en) 2009-12-11 2011-06-16 Exelixis, Inc. Tgr5 agonists
US8013015B2 (en) 2008-10-02 2011-09-06 Board Of Regents, The University Of Texas System Small molecule inhibitors of ghrelin O-acyltransferase
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011127106A1 (en) 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2011138427A2 (en) 2010-05-07 2011-11-10 Boehringer Ingelheim International Gmbh Pyridazinones as gpr119 agonists
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011146324A1 (en) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Spiro isoxazoline compounds as sstr5 antagonists
WO2011146335A1 (en) 2010-05-17 2011-11-24 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2011150067A1 (en) 2010-05-28 2011-12-01 Glaxosmithkline Llc Treatment of blood lipid abnormalities and other conditions
WO2011147951A1 (en) 2010-05-28 2011-12-01 Prosidion Limited Cycloamino derivatives as gpr119 antagonists
WO2011153435A1 (en) 2010-06-04 2011-12-08 Metabolex, Inc. Preparation of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2011163090A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2012011125A1 (en) * 2010-07-23 2012-01-26 Connexios Life Sciences Pvt. Ltd. Agonists of gpr40
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US20120053180A1 (en) 2010-08-27 2012-03-01 Chemizon, A Division Of Optomagic Co., Ltd. Cyclohexane analogues as gpr119 agonists
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
WO2012028602A1 (en) 2010-08-30 2012-03-08 Nycomed Gmbh Solid phase synthesis of h(gly2)glp-2
WO2012037393A1 (en) 2010-09-17 2012-03-22 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2012046792A1 (ja) 2010-10-08 2012-04-12 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2012046249A1 (en) 2010-10-08 2012-04-12 Cadila Healthcare Limited Novel gpr 119 agonists
WO2012070554A1 (ja) 2010-11-22 2012-05-31 国立大学法人京都大学 ペプチド
WO2012077655A1 (ja) 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
WO2012082947A1 (en) 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
WO2012080476A1 (en) 2010-12-17 2012-06-21 Boehringer Ingelheim International Gmbh Fused dihydropyrans as gpr119 modulators for the treatment of diabetes, obesity and related diseases
WO2012098217A1 (en) 2011-01-21 2012-07-26 Boehringer Ingelheim International Gmbh Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
WO2012103806A1 (en) 2011-01-31 2012-08-09 Centaurus Biopharma Co., Ltd. Bicyclic heteroaryl compounds as gpr119 receptor agonists
WO2012117996A1 (ja) 2011-02-28 2012-09-07 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2012138919A2 (en) 2011-04-08 2012-10-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012149236A1 (en) 2011-04-28 2012-11-01 Bristol-Myers Squibb Company Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013040093A2 (en) 2011-09-12 2013-03-21 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
WO2013054338A1 (en) 2011-07-06 2013-04-18 Cadila Healthcare Limited 2-thio-imidazole derivatives as tgr5 modulators
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013066869A1 (en) 2011-11-03 2013-05-10 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2013074388A1 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013096771A1 (en) 2011-12-21 2013-06-27 Ardelyx, Inc. Non-systemic tgr5 agonists
WO2013122821A1 (en) 2012-02-14 2013-08-22 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013125732A1 (en) 2012-02-24 2013-08-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013164484A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
WO2013167514A1 (en) 2012-05-07 2013-11-14 Boehringer Ingelheim International Gmbh New 2,3-dihydro-furo[2,3-c]pyridines, their use as modulators of the g-protein-coupled receptor gpr119 and pharmaceutical compositions comprising them
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
WO2014056938A1 (en) 2012-10-09 2014-04-17 Sanofi Pyrrolidinone derivatives as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2014066819A1 (en) 2012-10-26 2014-05-01 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
WO2014100025A1 (en) 2012-12-17 2014-06-26 Exelixis, Inc. Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
WO2014096440A2 (en) 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
WO2014100021A1 (en) 2012-12-17 2014-06-26 Exelixis, Inc. Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US20150018422A1 (en) * 2012-02-13 2015-01-15 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2015017710A1 (en) 2013-07-31 2015-02-05 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
WO2015052910A1 (en) 2013-10-07 2015-04-16 Takeda Pharmaceutical Company Limited Antagonists of somatostatin receptor subtype 5 (sstr5)
WO2015073281A1 (en) 2013-11-14 2015-05-21 Eli Lilly And Company Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
WO2015080446A1 (en) 2013-11-26 2015-06-04 Chong Kun Dang Pharmaceutical Corp. Amide derivatives for gpr119 agonist
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2015150565A1 (en) 2014-04-04 2015-10-08 Sanofi Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2015150564A1 (en) 2014-04-04 2015-10-08 Sanofi Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2015150563A1 (en) 2014-04-04 2015-10-08 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2015160772A1 (en) 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5
WO2015181275A1 (en) 2014-05-29 2015-12-03 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US20160009662A1 (en) * 2014-07-09 2016-01-14 Janssen Pharmaceutica Nv Pyrazine gpr40 agonists for the treatment of type ii diabetes
WO2016044467A1 (en) 2014-09-17 2016-03-24 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
WO2016054208A1 (en) 2014-10-03 2016-04-07 Mayo Foundation For Medical Education And Research Targeting tgr5 to treat disease
WO2016066818A1 (en) 2014-10-31 2016-05-06 Gubra Aps Compositions and peptides having dual glp-1r and glp-2r agonist activity
WO2016068453A1 (en) 2014-10-27 2016-05-06 Dong-A St Co., Ltd. Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US9340578B2 (en) 2013-07-15 2016-05-17 Syracuse University Inhibitors targeting human ghrelin O-acyltransferase
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
WO2016130809A1 (en) 2015-02-11 2016-08-18 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016168225A1 (en) 2015-04-15 2016-10-20 Eli Lilly And Company Ghrelin o-acyl transferase inhibitors
WO2016168222A1 (en) 2015-04-15 2016-10-20 Eli Lilly And Company Ghrelin o-acyl transferase inhibitors
WO2016205032A1 (en) 2015-06-16 2016-12-22 Eli Lilly And Company 2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives
WO2016205475A2 (en) 2015-06-19 2016-12-22 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2017002786A1 (ja) 2015-07-02 2017-01-05 サントリーホールディングス株式会社 Ｇｌｐ－２分泌促進用組成物
WO2017005765A1 (en) 2015-07-06 2017-01-12 Novo Nordisk A/S Novel peptides and peptide derivatives and uses thereof
WO2017027396A1 (en) 2015-08-07 2017-02-16 Intercept Pharmaceuticals, Inc. Methods for preparation of bile acids and derivatives thereof
US20170056373A1 (en) 2015-09-01 2017-03-02 Syracuse University Ghrelin o-acyltransferase inhibitors
WO2017053826A1 (en) 2015-09-24 2017-03-30 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
WO2017079062A1 (en) 2015-11-06 2017-05-11 Intercept Pharmaceuticals, Inc. Methods for the preparation of obeticholic acid and derivatives thereof
WO2017106818A1 (en) 2015-12-18 2017-06-22 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists
WO2017106112A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147742A1 (en) 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
WO2017175068A1 (en) 2016-04-08 2017-10-12 Mankind Pharma Ltd. Thiazolopyridine derivatives as gpr119 agonists
WO2017175066A1 (en) 2016-04-08 2017-10-12 Mankind Pharma Ltd. Heterocyclic gpr119 agonist compounds
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
WO2017222713A1 (en) 2016-06-24 2017-12-28 Indiana University Research & Technology Corporation A gpr119-based signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner
WO2018005801A2 (en) 2016-07-01 2018-01-04 Venenum Biodesign Llc Novel non-systemic tgr5 agonists
WO2018005794A2 (en) 2016-07-01 2018-01-04 Venenum Biodesign Llc Novel non-systemic tgr5 agonists
WO2018009778A1 (en) 2016-07-07 2018-01-11 Baylor College Of Medicine Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
WO2018024653A1 (en) 2016-08-05 2018-02-08 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2018035079A1 (en) 2016-08-16 2018-02-22 Hougland James L Human ghrelin o-acyl transferase inhibitors
WO2018064441A1 (en) 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc Crystalline forms of a bile acid derivative
WO2018071493A1 (en) 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104560A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018142363A1 (en) 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Ready to use compositions of glp-2 analogues through self-administrable devices
WO2018153849A1 (en) 2017-02-21 2018-08-30 Sanofi Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2018222701A1 (en) 2017-05-30 2018-12-06 Intercept Pharmaceuticals, Inc. Treatment of renal diseases with a bile acid derivative
WO2018226724A1 (en) 2017-06-05 2018-12-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of diabetic eye diseases with a bile acid derivatives
WO2018229252A1 (en) 2017-06-16 2018-12-20 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
WO2018237350A1 (en) 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES
WO2019040399A1 (en) 2017-08-22 2019-02-28 Shire-Nps Pharmaceuticals, Inc. GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS
WO2019090209A1 (en) 2017-11-06 2019-05-09 Shire-Nps Pharmaceuticals, Inc. Glp-2 analogs and peptibodies for administration before during, or after surgery
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019149659A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
WO2019149657A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
WO2019152889A1 (en) 2018-02-02 2019-08-08 John Mansell Compositions and methods for treatment of obesity and obesity-related disorders
WO2019149660A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
WO2019149959A1 (en) 2018-02-05 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Ghrelin o-acyltransferase inhibitors
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
AR043057A1 (es) 2002-10-30 2005-07-13 Vertex Pharma Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US20080090865A1 (en) 2005-01-28 2008-04-17 Min Ge Antidiabetic Bicyclic Compounds
EP1846379B1 (en) 2005-01-31 2009-08-19 Merck & Co., Inc. Antidiabetic bicyclic compounds
JP5075641B2 (ja) 2006-01-31 2012-11-21 武田薬品工業株式会社 遺伝子改変動物およびその用途
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
EP2021327B1 (en) 2006-05-15 2012-04-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US8119617B2 (en) * 2006-08-23 2012-02-21 Novartis Ag aSMase inhibitors
WO2008063768A2 (en) 2006-10-12 2008-05-29 Case Western Reserve University Compositions and methods for treating metabolic diseases
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008054675A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
US7750048B2 (en) 2006-11-15 2010-07-06 Janssen Pharmaceutica Nv GPR40 agonists
WO2009034388A1 (en) 2007-09-10 2009-03-19 Prosidion Limited Compounds for the treatment of metabolic disorders
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
CN101796018A (zh) 2007-09-21 2010-08-04 塞诺菲-安万特股份有限公司 (环丙基苯基)苯基草酰胺类化合物、其生产方法以及作为药物的用途
MY149648A (en) 2007-09-21 2013-09-30 Sanofi Aventis Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
BRPI0818687A2 (pt) 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
EP2215068B1 (en) 2007-10-29 2012-06-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2009269772A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Piperidinyl GPCR agonists
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2389369A1 (en) 2009-01-23 2011-11-30 Schering Corporation Pentafluorosulpholane-containing antidiabetic compounds
WO2010085525A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
JP2012515782A (ja) 2009-01-23 2012-07-12 シェーリング コーポレイション 抗糖尿病性架橋および縮合化合物
AR075051A1 (es) 2009-02-05 2011-03-02 Schering Corp Compuestos antidiabeticos que contienen ftalazina
EP2399914A4 (en) 2009-02-18 2012-08-29 Takeda Pharmaceutical FUSED HETEROCYCLIC CORE COMPOUND
CN102421739A (zh) 2009-04-22 2012-04-18 安斯泰来制药株式会社 羧酸化合物
JP2012136438A (ja) 2009-04-22 2012-07-19 Astellas Pharma Inc テトラゾール化合物
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AU2010312365A1 (en) 2009-10-30 2012-06-07 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
CN104710381A (zh) 2009-12-25 2015-06-17 持田制药株式会社 新的3-羟基-5-芳基异噻唑衍生物
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012033149A1 (ja) 2010-09-10 2012-03-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
DK2646425T3 (en) 2010-12-01 2015-08-24 Boehringer Ingelheim Int Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome.
JP5945545B2 (ja) 2011-02-17 2016-07-05 武田薬品工業株式会社 光学活性なジヒドロベンゾフラン誘導体の製造法
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
RU2013152631A (ru) 2011-04-27 2015-06-10 Мотида Фармасьютикал Ко., Лтд. Новое 3-гидроксиизотиазол-1-окидное производное
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
TWI537262B (zh) 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
WO2013057743A1 (en) 2011-10-21 2013-04-25 Connexios Life Sciences Pvt. Ltd Process for the preparation of an aryl oxime and salts thereof
CN103429581B (zh) 2012-01-12 2015-08-26 江苏恒瑞医药股份有限公司 多环类衍生物、其制备方法及其在医药上的应用
GB2498976A (en) 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
GB2498968A (en) 2012-02-01 2013-08-07 Prosidion Ltd Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist
JP6121339B2 (ja) 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
KR20140138243A (ko) 2012-02-28 2014-12-03 피라말 엔터프라이지즈 리미티드 G 단백질 연결 수용체 작용물질로서의 페닐알칸산 유도체
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
WO2013154163A1 (ja) 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
US8809376B2 (en) 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014052379A1 (en) 2012-09-26 2014-04-03 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
EP2925748B1 (en) 2012-11-28 2017-01-11 Boehringer Ingelheim International GmbH Indanyloxydihydrobenzofuranylacetic acids as modulators of the g-protein coupled receptor 40 (gpr40) and of the free fatty acid receptor 1 (ffar1) for the treatment of metabolic diseases
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
JP6314335B2 (ja) 2013-02-06 2018-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014131764A1 (en) 2013-02-27 2014-09-04 Haldor Topsøe A/S Process for preparing ketene in the presence of a fluidized bed material with a surface area of up to 600 m2/g
CN104059039B (zh) 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
CN104109115B (zh) 2013-04-16 2016-11-23 中国科学院上海药物研究所 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
AR096041A1 (es) 2013-04-17 2015-12-02 Piramal Entpr Ltd Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
CN104870429B (zh) 2013-05-22 2017-05-03 四川海思科制药有限公司 苯并呋喃衍生物、其制备方法及其在医药上的应用
CN104507921B (zh) 2013-07-02 2017-02-22 四川海思科制药有限公司 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
CN105143181B (zh) 2013-07-26 2017-12-26 四川海思科制药有限公司 三元并环羧酸类衍生物、其制备方法及其在医药上的应用
PL3031799T3 (pl) 2013-08-09 2018-09-28 Takeda Pharmaceutical Company Limited Związek aromatyczny
CN104418801B (zh) 2013-08-19 2016-10-05 上海润诺生物科技有限公司 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
CN105473595A (zh) 2013-08-23 2016-04-06 福建海西新药创制有限公司 治疗糖尿病的羧酸化合物
WO2015028960A1 (en) 2013-08-28 2015-03-05 Piramal Enterprises Limited Substituted heterocyclic derivatives as gpr agonists and uses thereof
CN105246875A (zh) 2013-09-03 2016-01-13 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
EP3049396B1 (en) 2013-09-26 2017-11-15 Boehringer Ingelheim International GmbH Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104592211B (zh) 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
EP3068768B1 (en) 2013-11-15 2019-07-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3074375B1 (en) 2013-11-28 2018-04-04 Boehringer Ingelheim International GmbH New indanyloxyphenylcyclopropanecarboxylic acids
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
TW201609722A (zh) 2013-12-13 2016-03-16 美國禮來大藥廠 新穎三唑并吡啶化合物
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
KR20160095117A (ko) 2014-01-10 2016-08-10 일라이 릴리 앤드 캄파니 페닐-트리아졸로-피리딘 화합물
JP6170255B2 (ja) 2014-01-10 2017-07-26 イーライ リリー アンド カンパニー イソプロピルトリアゾロピリジン化合物
WO2015117147A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3164538A1 (en) 2014-07-02 2017-05-10 Arçelik Anonim Sirketi Built-in household appliance unpowered control and status indication device
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
WO2016032120A1 (ko) 2014-08-27 2016-03-03 씨제이헬스케어 주식회사 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
TW201629033A (zh) 2014-10-08 2016-08-16 健生藥品公司 作為治療第二型糖尿病之ｇｐｒ４０促效劑的經取代苯并噻吩基衍生物
KR101726819B1 (ko) 2014-10-27 2017-04-13 동아에스티 주식회사 Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
JP6816107B2 (ja) 2015-08-07 2021-01-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
WO2017027312A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
WO2017027309A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
WO2017027310A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
EP3347358B1 (en) 2015-09-09 2019-11-27 Boehringer Ingelheim International GmbH [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
US10106553B2 (en) 2016-04-11 2018-10-23 Janssen Pharmaceutica Nv Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
WO2018081047A1 (en) 2016-10-25 2018-05-03 Janssen Pharmaceutica Nv Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
WO2018077699A1 (en) 2016-10-25 2018-05-03 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7008704B2 (ja) 2016-11-28 2022-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
KR102007633B1 (ko) 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
US10793530B2 (en) 2017-01-26 2020-10-06 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10919859B2 (en) 2017-01-26 2021-02-16 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
JP6968181B2 (ja) 2017-01-26 2021-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
WO2018138030A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
GB201704714D0 (en) 2017-03-24 2017-05-10 Caldan Therapeutics Ltd Pharmaceutical compounds
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
WO2018181847A1 (ja) * 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物
CN107162921B (zh) 2017-05-27 2019-12-13 中国药科大学 一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
US11225471B2 (en) 2017-11-16 2022-01-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US11964938B2 (en) 2018-01-08 2024-04-23 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists
US20220152164A1 (en) 2019-03-22 2022-05-19 Kallyope, Inc. Gpcr combination therapies
US20220226298A1 (en) 2019-05-29 2022-07-21 Kallyope, Inc. Gpr40 agonists
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
WO2021113363A1 (en) 2019-12-03 2021-06-10 Kallyope, Inc. Sstr5 antagonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021174046A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
EP4320129A1 (en) 2021-04-06 2024-02-14 Kallyope, Inc. Gpr119 agonists
WO2023097187A1 (en) 2021-11-23 2023-06-01 Kallyope, Inc. Ampk activators
WO2023250323A1 (en) 2022-06-24 2023-12-28 Kallyope, Inc. Gpr119 and gpr40 agonist combination therapies for gut-brain axis disorders

Patent Citations (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014066A1 (en) 1992-01-09 1993-07-22 James Black Foundation Limited Amino acid derivatives with anticholecystokinin activity
WO1993016982A1 (en) 1992-02-20 1993-09-02 James Black Foundation Limited Bicyclo[2.2.2.]octane derivatives as cholestocystokinin inhibitors
WO1994024151A1 (en) 1993-04-15 1994-10-27 Glaxo Inc. 1,5 benzodiazepine derivatives having cck and/or gastrin antagonistic activity
US5846514A (en) 1994-03-25 1998-12-08 Isotechnika, Inc. Enhancement of the efficacy of nifedipine by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1995028419A1 (en) 1994-04-14 1995-10-26 Glaxo Wellcome Inc. Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
WO1995028399A1 (en) 1994-04-15 1995-10-26 Glaxo Wellcome Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
WO1995028391A1 (en) 1994-04-15 1995-10-26 Glaxo Wellcome Inc. Cck or gastrin modulating 1,5 benzodiazepines derivatives
WO1996011940A1 (en) 1994-10-14 1996-04-25 Glaxo Wellcome Inc. Acyl amino acetamide derivatives with agonist activity for cck-a receptors
WO1996011691A1 (en) 1994-10-14 1996-04-25 Glaxo Wellcome Inc. Use of 1,5-benzodiazepine derivatives for the control of gastric emptying in patients with non-insulin dependent diabetes mellitus
WO1996032414A1 (en) 1995-04-14 1996-10-17 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO1997039031A1 (en) 1996-04-12 1997-10-23 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
WO1998051686A1 (fr) 1997-05-13 1998-11-19 Sanofi-Synthelabo N-triazolyl-2-indolecarboxamides et leur utilisation comme agonistes de cck-a
WO1999015525A1 (fr) 1997-09-19 1999-04-01 Sanofi-Synthelabo Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant
WO2000068209A2 (en) 1999-05-06 2000-11-16 Glaxo Group Limited 1,5-benzodiazepine derivatives as cck-a receptor agonists
WO2001077108A1 (en) 2000-04-07 2001-10-18 Sanofi-Synthelabo Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
WO2002034743A1 (en) 2000-10-26 2002-05-02 Sanofi-Synthelabo Triazole derivatives and pharmaceutical compositions comprising them
WO2002044150A1 (en) 2000-11-28 2002-06-06 Sanofi-Synthelabo Chemical process and new intermediates
WO2002066511A2 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
WO2003104816A1 (en) 2002-06-07 2003-12-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (sstr5)
WO2005035793A2 (en) 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
WO2005067368A2 (en) 2003-11-21 2005-07-28 Nps Allelix Corp. Production of glucagon like peptide 2 and analogs
WO2005116034A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
US20060177438A1 (en) 2005-02-08 2006-08-10 New England Medical Center Methods of altering absorption of hydrophobic compounds
WO2006117565A2 (en) 2005-05-04 2006-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
WO2006128803A1 (en) 2005-06-02 2006-12-07 F. Hoffmann-La Roche Ag Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
WO2007003962A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007067828A2 (en) 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
WO2007120689A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2007120688A2 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2007120655A2 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2008025798A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders
WO2008028117A2 (en) 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008056155A1 (en) 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
WO2008067222A1 (en) 2006-11-28 2008-06-05 Kalypsys, Inc. Heterocyclic modulators of tgr5
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
WO2008083238A2 (en) 2006-12-28 2008-07-10 Metabolex Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2008091540A2 (en) 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
WO2008091631A1 (en) 2007-01-26 2008-07-31 Merck & Co., Inc. Substituted aminopyrimidines as cholecystokinin-1 receptor modulators
WO2008097428A2 (en) 2007-02-02 2008-08-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008109702A1 (en) 2007-03-08 2008-09-12 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
WO2008137436A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
WO2009012275A1 (en) 2007-07-17 2009-01-22 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
WO2009026241A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5
WO2009050309A1 (es) 2007-10-17 2009-04-23 Universidad De Cordoba Isoformas del receptor de somatostatina humano tipo 5 producidas por procesamiento alternativo y parejas de oligonucleótidos para su detección por pcr
WO2009105722A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009105717A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009105715A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2009119733A1 (ja) 2008-03-26 2009-10-01 パナソニック電工株式会社 発光装置
WO2009123992A1 (en) 2008-03-31 2009-10-08 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
WO2009126535A1 (en) 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009143049A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2009141238A1 (en) 2008-05-19 2009-11-26 F. Hoffmann-La Roche Ag Gpr119 receptor agonists
WO2010008739A2 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
WO2010008851A1 (en) 2008-06-24 2010-01-21 Berger Terry A A compressible fluid pumping system
WO2010006191A1 (en) 2008-07-11 2010-01-14 Irm Llc 4-phenoxymethylpiperidines as modulators of gpr119 activity
WO2010009183A1 (en) 2008-07-16 2010-01-21 Bristol-Myers Squibb Company Pyridone and pyridazone analogues as gpr119 modulators
WO2010014739A2 (en) 2008-07-29 2010-02-04 Kalypsys, Inc. Heterocyclic modulators of tgr5
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2010013849A1 (ja) 2008-08-01 2010-02-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2010016846A1 (en) 2008-08-08 2010-02-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2010042145A1 (en) 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
US8013015B2 (en) 2008-10-02 2011-09-06 Board Of Regents, The University Of Texas System Small molecule inhibitors of ghrelin O-acyltransferase
WO2010039461A2 (en) 2008-10-03 2010-04-08 The Johns Hopkins University Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2010059859A1 (en) 2008-11-19 2010-05-27 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2010059853A1 (en) 2008-11-19 2010-05-27 Intercept Pharmaceuticals, Inc. Tgr5 modulators and method of use thereof
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
WO2010093845A1 (en) 2009-02-12 2010-08-19 Exelixis, Inc. Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
WO2011008663A1 (en) 2009-07-15 2011-01-20 Eli Lilly And Company Gpr119 agonists
WO2011025006A1 (ja) 2009-08-31 2011-03-03 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011044001A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011050174A1 (en) 2009-10-23 2011-04-28 Ferring B.V. Peptidic glp-2 agonists
WO2011061679A1 (en) 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
WO2011071565A1 (en) 2009-12-11 2011-06-16 Exelixis, Inc. Tgr5 agonists
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011127106A1 (en) 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
WO2011138427A2 (en) 2010-05-07 2011-11-10 Boehringer Ingelheim International Gmbh Pyridazinones as gpr119 agonists
WO2011146335A1 (en) 2010-05-17 2011-11-24 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2011146324A1 (en) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Spiro isoxazoline compounds as sstr5 antagonists
WO2011150067A1 (en) 2010-05-28 2011-12-01 Glaxosmithkline Llc Treatment of blood lipid abnormalities and other conditions
WO2011147951A1 (en) 2010-05-28 2011-12-01 Prosidion Limited Cycloamino derivatives as gpr119 antagonists
WO2011153435A1 (en) 2010-06-04 2011-12-08 Metabolex, Inc. Preparation of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2011163090A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2012011125A1 (en) * 2010-07-23 2012-01-26 Connexios Life Sciences Pvt. Ltd. Agonists of gpr40
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
US20120053180A1 (en) 2010-08-27 2012-03-01 Chemizon, A Division Of Optomagic Co., Ltd. Cyclohexane analogues as gpr119 agonists
WO2012028602A1 (en) 2010-08-30 2012-03-08 Nycomed Gmbh Solid phase synthesis of h(gly2)glp-2
WO2012037393A1 (en) 2010-09-17 2012-03-22 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2012046249A1 (en) 2010-10-08 2012-04-12 Cadila Healthcare Limited Novel gpr 119 agonists
WO2012046792A1 (ja) 2010-10-08 2012-04-12 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2012070554A1 (ja) 2010-11-22 2012-05-31 国立大学法人京都大学 ペプチド
WO2012077655A1 (ja) 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
WO2012082947A1 (en) 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
WO2012080476A1 (en) 2010-12-17 2012-06-21 Boehringer Ingelheim International Gmbh Fused dihydropyrans as gpr119 modulators for the treatment of diabetes, obesity and related diseases
WO2012098217A1 (en) 2011-01-21 2012-07-26 Boehringer Ingelheim International Gmbh Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
WO2012103806A1 (en) 2011-01-31 2012-08-09 Centaurus Biopharma Co., Ltd. Bicyclic heteroaryl compounds as gpr119 receptor agonists
WO2012117996A1 (ja) 2011-02-28 2012-09-07 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2012138919A2 (en) 2011-04-08 2012-10-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012149236A1 (en) 2011-04-28 2012-11-01 Bristol-Myers Squibb Company Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013054338A1 (en) 2011-07-06 2013-04-18 Cadila Healthcare Limited 2-thio-imidazole derivatives as tgr5 modulators
WO2013040093A2 (en) 2011-09-12 2013-03-21 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013066869A1 (en) 2011-11-03 2013-05-10 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2013074388A1 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013096771A1 (en) 2011-12-21 2013-06-27 Ardelyx, Inc. Non-systemic tgr5 agonists
US20150018422A1 (en) * 2012-02-13 2015-01-15 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013122821A1 (en) 2012-02-14 2013-08-22 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013125732A1 (en) 2012-02-24 2013-08-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013164484A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
WO2013167514A1 (en) 2012-05-07 2013-11-14 Boehringer Ingelheim International Gmbh New 2,3-dihydro-furo[2,3-c]pyridines, their use as modulators of the g-protein-coupled receptor gpr119 and pharmaceutical compositions comprising them
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
WO2014056938A1 (en) 2012-10-09 2014-04-17 Sanofi Pyrrolidinone derivatives as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2014066819A1 (en) 2012-10-26 2014-05-01 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
WO2014100025A1 (en) 2012-12-17 2014-06-26 Exelixis, Inc. Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
WO2014100021A1 (en) 2012-12-17 2014-06-26 Exelixis, Inc. Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
WO2014096440A2 (en) 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US9340578B2 (en) 2013-07-15 2016-05-17 Syracuse University Inhibitors targeting human ghrelin O-acyltransferase
WO2015017710A1 (en) 2013-07-31 2015-02-05 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
WO2015052910A1 (en) 2013-10-07 2015-04-16 Takeda Pharmaceutical Company Limited Antagonists of somatostatin receptor subtype 5 (sstr5)
WO2015073281A1 (en) 2013-11-14 2015-05-21 Eli Lilly And Company Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
WO2015080446A1 (en) 2013-11-26 2015-06-04 Chong Kun Dang Pharmaceutical Corp. Amide derivatives for gpr119 agonist
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
US20160332968A1 (en) * 2014-02-06 2016-11-17 Harry CHOBANIAN Antidiabetic compounds
WO2015150565A1 (en) 2014-04-04 2015-10-08 Sanofi Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2015150563A1 (en) 2014-04-04 2015-10-08 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2015150564A1 (en) 2014-04-04 2015-10-08 Sanofi Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2015160772A1 (en) 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
WO2015181275A1 (en) 2014-05-29 2015-12-03 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US20160009662A1 (en) * 2014-07-09 2016-01-14 Janssen Pharmaceutica Nv Pyrazine gpr40 agonists for the treatment of type ii diabetes
WO2016044467A1 (en) 2014-09-17 2016-03-24 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
WO2016054208A1 (en) 2014-10-03 2016-04-07 Mayo Foundation For Medical Education And Research Targeting tgr5 to treat disease
WO2016068453A1 (en) 2014-10-27 2016-05-06 Dong-A St Co., Ltd. Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2016066818A1 (en) 2014-10-31 2016-05-06 Gubra Aps Compositions and peptides having dual glp-1r and glp-2r agonist activity
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
WO2016130809A1 (en) 2015-02-11 2016-08-18 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016168225A1 (en) 2015-04-15 2016-10-20 Eli Lilly And Company Ghrelin o-acyl transferase inhibitors
WO2016168222A1 (en) 2015-04-15 2016-10-20 Eli Lilly And Company Ghrelin o-acyl transferase inhibitors
WO2016205032A1 (en) 2015-06-16 2016-12-22 Eli Lilly And Company 2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives
WO2016205475A2 (en) 2015-06-19 2016-12-22 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2017002786A1 (ja) 2015-07-02 2017-01-05 サントリーホールディングス株式会社 Ｇｌｐ－２分泌促進用組成物
WO2017005765A1 (en) 2015-07-06 2017-01-12 Novo Nordisk A/S Novel peptides and peptide derivatives and uses thereof
WO2017027396A1 (en) 2015-08-07 2017-02-16 Intercept Pharmaceuticals, Inc. Methods for preparation of bile acids and derivatives thereof
US20170056373A1 (en) 2015-09-01 2017-03-02 Syracuse University Ghrelin o-acyltransferase inhibitors
WO2017053826A1 (en) 2015-09-24 2017-03-30 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
WO2017079062A1 (en) 2015-11-06 2017-05-11 Intercept Pharmaceuticals, Inc. Methods for the preparation of obeticholic acid and derivatives thereof
WO2017106112A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
WO2017106818A1 (en) 2015-12-18 2017-06-22 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147742A1 (en) 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
WO2017175068A1 (en) 2016-04-08 2017-10-12 Mankind Pharma Ltd. Thiazolopyridine derivatives as gpr119 agonists
WO2017175066A1 (en) 2016-04-08 2017-10-12 Mankind Pharma Ltd. Heterocyclic gpr119 agonist compounds
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
WO2017222713A1 (en) 2016-06-24 2017-12-28 Indiana University Research & Technology Corporation A gpr119-based signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner
WO2018005794A2 (en) 2016-07-01 2018-01-04 Venenum Biodesign Llc Novel non-systemic tgr5 agonists
WO2018005801A2 (en) 2016-07-01 2018-01-04 Venenum Biodesign Llc Novel non-systemic tgr5 agonists
WO2018009778A1 (en) 2016-07-07 2018-01-11 Baylor College Of Medicine Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2018024653A1 (en) 2016-08-05 2018-02-08 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
WO2018035079A1 (en) 2016-08-16 2018-02-22 Hougland James L Human ghrelin o-acyl transferase inhibitors
WO2018064441A1 (en) 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc Crystalline forms of a bile acid derivative
WO2018071493A1 (en) 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104560A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018142363A1 (en) 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Ready to use compositions of glp-2 analogues through self-administrable devices
WO2018153849A1 (en) 2017-02-21 2018-08-30 Sanofi Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2018222701A1 (en) 2017-05-30 2018-12-06 Intercept Pharmaceuticals, Inc. Treatment of renal diseases with a bile acid derivative
WO2018226724A1 (en) 2017-06-05 2018-12-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of diabetic eye diseases with a bile acid derivatives
WO2018229252A1 (en) 2017-06-16 2018-12-20 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
WO2018237350A1 (en) 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES
WO2019040399A1 (en) 2017-08-22 2019-02-28 Shire-Nps Pharmaceuticals, Inc. GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019090209A1 (en) 2017-11-06 2019-05-09 Shire-Nps Pharmaceuticals, Inc. Glp-2 analogs and peptibodies for administration before during, or after surgery
WO2019149659A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
WO2019149657A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
WO2019152889A1 (en) 2018-02-02 2019-08-08 John Mansell Compositions and methods for treatment of obesity and obesity-related disorders
WO2019149660A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
WO2019149959A1 (en) 2018-02-05 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Ghrelin o-acyltransferase inhibitors

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
"Remington: The Science and Practice of Pharmacy", 2005, JOHN WILEY AND SONS, INC
BERGE S.M. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1997, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24
CURR., PHARM. DES., vol. 6, no. 10, 2000
EVANS, E. ANTHONY, SYNTHESIS OF RADIOLABELED COMPOUNDS, J. RADIOANAL. CHEM., vol. 64, no. 1-2, 1981, pages 9 - 32
GEORGE W.VARMA, RAJENDER S.: "The Synthesis of Radiolabeled Compounds via Organometallic Intermediates", TETRAHEDRON, vol. 45, no. 21, 1989, pages 6601 - 21
HIGUCHI, T. ET AL.: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
SANATH K. MEEGALLA, HUANG HUI, MARTIN TONYA, XU JUNE, ZHAO SHUYUAN, LIU JIANYING, HALL MEGHAN, GUNNET JOE, WANG YUANPING, RADY BRI: "Discovery of a novel potent GPR40 full agonist", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 28, no. 4, 12 January 2018 (2018-01-12), AMSTERDAM, NL, pages 720 - 726, XP055757324, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2018.01.013 *
See also references of EP4110788A4

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
US12264171B2 (en) 2020-02-28 2025-04-01 Kallyope, Inc. GPR40 agonists
US12018015B2 (en) 2021-06-18 2024-06-25 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
US12534450B2 (en) 2021-06-18 2026-01-27 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
US12428427B2 (en) 2021-12-16 2025-09-30 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
WO2023250323A1 (en) * 2022-06-24 2023-12-28 Kallyope, Inc. Gpr119 and gpr40 agonist combination therapies for gut-brain axis disorders
WO2025136929A1 (en) * 2023-12-19 2025-06-26 Kallyope, Inc. Gpr40 agonists
WO2025137315A1 (en) * 2023-12-22 2025-06-26 Kallyope, Inc. Combination therapy for treatment of metabolic disease
WO2025137310A1 (en) * 2023-12-22 2025-06-26 Kallyope, Inc. Crystalline gpr40 agonist and methods of making

Also Published As

Publication number Publication date
JP7745559B2 (ja) 2025-09-29
BR112022017039A2 (pt) 2022-11-16
CL2022002323A1 (es) 2023-03-31
MX2022010548A (es) 2022-09-23
PH12022552277A1 (en) 2024-03-04
CA3173731A1 (en) 2021-09-02
EP4110788A4 (en) 2024-08-28
AU2021228729A1 (en) 2022-09-22
JP2023516187A (ja) 2023-04-18
US20220289772A1 (en) 2022-09-15
IL295825A (en) 2022-10-01
TW202140440A (zh) 2021-11-01
KR20220149558A (ko) 2022-11-08
UY39107A (es) 2021-09-30
CN115667277A (zh) 2023-01-31
US20250276989A1 (en) 2025-09-04
US12264171B2 (en) 2025-04-01
EP4110788A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
US12264171B2 (en) GPR40 agonists
EP4110760A1 (en) Gpr40 agonists
CN114945560B (zh) Gpr119激动剂
EP3976576A1 (en) Gpr40 agonists
EP4073075A1 (en) Sstr5 antagonists
AU2021275038A1 (en) AMPK activators
EP4320129A1 (en) Gpr119 agonists
HK40085450A (en) Gpr40 agonists
WO2025136929A1 (en) Gpr40 agonists
HK40085449A (en) Gpr40 agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21759945

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022551554

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3173731

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202217049825

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022017039

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2021228729

Country of ref document: AU

Date of ref document: 20210226

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227033245

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021759945

Country of ref document: EP

Effective date: 20220928

ENP Entry into the national phase

Ref document number: 112022017039

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220825

WWW Wipo information: withdrawn in national office

Ref document number: 791877

Country of ref document: NZ